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ABSTRACT 
 
 
In healthy tissues blood vessels undergo a process known as vascular stabilisation in 
order to tightly control vascular permeability and ensure an optimal perfusion of the tissue. 
Vascular stabilisation is accomplished through endothelial cell-cell contact formation, 
basement membrane deposition and mural cell recruitment. Conversely, tumor vessels lack 
vascular stability features leading to increased interstitial fluid pressure, reduced drug 
delivery and easier metastatic dissemination. Vascular Endothelial (VE)-cadherin plays a 
crucial role in adherens junction (AJ) formation between endothelial cells (ECs) and in the 
regulation of vascular permeability. Given this, we sought to determine in more details 
how VE-cadherin promotes the expression of vascular stability genes in ECs. 
We found that the expression and clustering of VE-cadherin at AJs upregulates a subset 
of endothelial-specific genes encoding the tight junction protein claudin-5, Vascular 
Endothelial-Protein Tyrosine Phosphatase (VE-PTP) and von Willebrand factor (vWf). 
Most importantly, these genes are well-known for their key role in promoting vascular 
stabilisation. In the absence of VE-cadherin claudin-5, VE-PTP and vWf are repressed by 
the combined activity of the transcription factor Forkhead-box O1 (FoxO1), β-catenin and 
Polycomb Group (PcG) proteins, a family of epigenetic repressors of transcription. Here 
we show that FoxO1 and β-catenin interact with PcG proteins in ECs and that they work as 
PcG protein recruiters on claudin-5, VE-PTP and vWf promoters. Strikingly, we found also 
that VE-cadherin is able to sequester part of Enhancer of Zeste homolog 2 (Ezh2), a key 
PcG protein, out of the nucleus in a β-catenin- and p120-catenin-dependent manner. 
Preventing p120-dependent Ezh2 sequestration at the plasma membrane leads to the 
repression of claudin-5, VE-PTP and vWf, thus suggesting that the sequestered pool of 
Ezh2 is functionally relevant for gene expression. Since in human ovarian cancer EZH2 is 
often upregulated in tumor vessels, we took advantage of this condition to demonstrate that 
CLAUDIN-5 expression is strongly downregulated when EZH2 expression is increased. 
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This suggests that CLAUDIN-5 undergoes an epigenetic regulation exerted by PcG 
proteins in vivo as well. To conclude, our findings prove for the first time that AJ 
organisation can influence gene expression at the epigenetic level and provide new insights 
into the understanding of vascular stabilisation paving the way for developing new 
therapies for diseases characterized by vessel instability such as cancer. 
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INTRODUCTION 
 
Development of the vascular system in mammals  
 
Single cells and organisms as small as Caenorhabditis elegans and Drosophila  
melanogaster do not have a cardiocirculatory system because they rely on the simple 
process of diffusion of oxygen and nutrients through their different cellular compartments 
1. On the contrary, large multicellular organisms would not survive without a 
cardiocirculatory system able to convey oxygen and nutrients to all tissues. The 
cardiocirculatory system is composed of an organ, the heart, which drives the blood 
circulation, and a vascular tree of arteries, veins and capillaries that convey blood and 
fluids to all the districts of the body. In addition, the vascular system has other fundamental 
functions such as to discard waste products and provide a fast track for patrolling immune 
cells  1-3.  
In mammals the formation of the vascular system takes place through two different 
sequential processes: vasculogenesis and angiogenesis 2, 4. Vasculogenesis is defined as the 
de novo formation of blood vessels starting from mesodermal precursor cells or angioblasts 
that form clumps known as blood islands in the embryo (Figure 1). In mice this process 
takes place between embryonic day E6.5 and E9.5. Vasculogenesis starts at E6.5 in 
extrambryonic tissues and between E7 and E7.5 in intraembryonic tissues with the 
appearence of dispersed T-cell Acute lymphocitic Lymphocitic Leukaemia protein 
1+/Vascular Endothelial Growth Factor Receptor 2+ (VEGFR-2 also known as Foetal liver 
kinase 1, Flk1) (TAL1+/Flk1+) angioblasts. Later on, TAL1+/Flk1- progenitors residing 
inside the blood island differentiate into haematopoietic cells while more external 
TAL1+/Flk1+ cells become endothelial cells (ECs)  5. Of note, the expression of these 
markers precedes the expression of well-established EC markers such as Platelet 
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Endothelial Cell Adhesion Molecule (PECAM), CD34, and VE-cadherin, which are 
detected only from E8 onwards. Subsequently, blood islands fuse together to create a 
network of blood vessels called primitive vascular plexus, needed to convey blood to the 
developing tissues once the heart starts to beat around E8.5. At this point, the primitive 
network of blood vessels must undergo a massive expansion and remodelling phase, a 
process referred to as angiogenesis. Angiogenesis, by definition, is the process of new 
vessel formation starting from pre-existing ones  2, 4, 6. During the angiogenic phase, the 
primitive network of vessels must reshape into a highly organized and hierarchical 
structure composed of larger vessels ramifying into small ones. Vessels must also acquire a 
further specialized identity in term of arteries, veins, capillaries and lymphatics (Figure 1). 
Arteries cope with strong haemodynamic forces and consist of a layer of ECs surrounded 
by multiple layers of smooth muscle cells that provide contractility and structural support. 
Veins, conversely, support a lower blood pressure and therefore are enclosed in a thinner 
layer of smooth muscle cells. Capillaries are the structures where the exchange of gases 
and nutrients takes place. They present a very thin vessel wall associated with pericytes: 
perivascular cells able to provide a degree of contractility and which help regulate 
permeability. Lymphatic vessels, instead, are needed to drain interstitial fluids from the 
tissues in order to take them back into the venous circulation  1-3, 7.  
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Figure 1 The development of the vascular network 
During embryonic development endothelial precursor cells (angioblasts) form aggregates called blood 
islands that later on will fuse together to create cord-like structures and the primary capillary plexus. 
These events occur during the vasculogenesis phase. Once the heart starts beating the primitive plexus 
must undergo a remodelling phase that will provide the embryo with a hierarchical network of arteries, 
capillaries, veins and lymphatics  8. 
 
 
Angiogenesis does not occur exclusively during embryo development but also during 
adult life in both physiological and pathological conditions. Regardless of the situation in 
which angiogenesis takes place, similar events are involved in the formation of new 
vessels. At the onset of sprouting, a stimulus (such as hypoxia) triggers the local 
production of proangiogenic molecules, such as Vascular Endothelial Growth Factors 
(VEGFs), which stimulate new vessel formation (Figure 2). First, ECs degrade the 
surrounding extracellular matrix by upregulating matrix metalloproteases (MMPs). These 
events are important both for allowing EC migration and for freeing pro/antiangiogenic 
molecules trapped inside the extracellular matrix, which finely regulate vessel sprouting. 
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Within the growing vessel, ECs undergo specification into tip and stalk cell depending on 
their position in the sprout. A tip cell is defined as the EC that drives sprout growth by 
probing the environment following, for instance, VEGF gradients, while stalk cells follow 
the tip cell, convey strength and support to the sprout and participate in lumen formation  3, 
9, 10. Among the numerous signalling pathways involved in tip and stalk cell specification, 
VEGFR and Notch pathways play a pivotal role. Tip cells respond to VEGF gradients via 
VEGFR2-mediated filopodia formation and upregulation of Delta Like 4 (DLL4), which in 
turn engages Notch1 receptors expressed by stalk cells (Figure 2). As a result, Notch1 
receptor activation represses tip cell phenotype in stalk cells  3, 8. Stalk cells produce fewer 
filopodia compared to tip cells and are more proliferative. Furthermore, they establish 
junctions with neighbouring cells and produce basement membrane components to ensure 
the stability of the sprout. It is worth to notice that tip and stalk cell identities are transient 
and that during sprout growth cell position might shuffle and tip/stalk roles can be 
redefined  9. 
In order to expand the vessel network, ECs undergo iterative cycles of sprouting, 
branching and tubulogenesis. Stalk cells organize to form a hollow lumen that permits 
blood flow. At least two different mechanisms have been proposed for lumen formation: 
cell hollowing and cord hollowing (Figure 2). The former mechanism has been observed in 
intersomitic vessels and requires the coalescence of intracellular vacuoles, further 
connecting with vacuoles of neighbouring ECs, leading to lumen formation. Cord 
hollowing, instead, consists in endothelial cell-cell junction reorganization, definition of 
apical-basal polarity and secretion from the apical (luminal) membrane of negatively 
charged glycoproteins that facilitate the opening of the lumen via electrostatic repulsion. 
Eventually, the growth of the sprout ends when another sprout is reached, and once the 
contact between tip cells is established, VE-cadherin-containing junctions form and 
stabilise the connection  3, 11. Recent studies in zebrafish embryo confirm the central role of  
VE-cadherin in regulating the early steps of vascular anastomosis  12. To conclude, newly 
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formed vessels deliver oxygen and nutrients to the hypoxic tissue, thus counterbalacing the 
proangiogenic stimuli involved in starting the entire angiogenic process and shifting EC 
behaviour towards a quiescent phenotype  3.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Angiogenic sprouting: tip cells, stalk cells and lumen formation 
(a) In hypoxic conditions, VEGF gradients promote sprouting. Tip cells extend filopodia to follow VEGF 
gradients, upregulate Dll4 expression and lead the sprout. (b) Notch1 expressed on stalk cells binds Dll4 
expressed on tip cells with the ensuing inhibition of VEGFR signalling and promotion of stalk cell 
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phenotype. (c and c') Stalk cells form junctions with neighbouring cells and subsequently a new lumen is 
formed. Adapted from Potente et al. 2011. 
 
 
Endothelial cell-cell junctions: adherens junctions and tight junctions 
 
ECs are equipped with highly organized cell-cell junctions that are responsible for many 
of the characteristics of ECs. ECs possess two types of cell-cell junctions: adherens 
junctions (AJs) and tight junctions (TJs). Unlike epithelial cells, ECs lack desmosomes, 
and display AJs and TJs frequently intermingled along the cell border. Endothelial AJs are 
formed by cell adhesion molecules of the cadherin family (Figure 3). Two types of 
cadherins are expressed by ECs: VE-cadherin and Neuronal (N)-cadherin. VE-cadherin 
expression is strictly limited to ECs, while N-cadherin is not EC-specific and mediates EC 
interaction with pericytes  13, 14. Both VE-cadherin and N-cadherin belong to the family of 
"classical" type I cadherins, made up of 5 extracellular domains located at the N-terminus, 
a transmembrane region and a cytoplasmic tail at the C-terminus serving as a binding 
platform for cadherin intracellular partners. Of note, cadherins engage Ca2+-dependent 
homophylic trans-interactions by binding to identical cadherins expressed on neighbouring 
cells. In addition, cadherins are also able to cluster laterally in cis (homophylic cis-
interactions) at cell-cell junctions forming a zipper-like structure along the cell border. The 
binding strength between two single classical cadherins is quite weak and transient  15, 16. 
Therefore, many cadherin molecules need to cooperate to allow for an effective 
intercellular adhesion. It has been calculated that the number of cadherin molecules at AJs 
ranges between 700 and 1200 per µm2  14, 16. In particular, the first two extracellular 
cadherin domains are reported to mediate homophylic interactions. More in detail, two 
contacting extracellular cadherin domains extend β-sheet arms which associate with 
hydrophobic grooves in their counterpart on the adjacent cell forming a "strand exchange 
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dimer"  16. These properties enable cadherins to promote homophylic cell-cell adhesion, 
which exerts a key role in generating and maintaining tissue integrity during development. 
The adhesive properties of cadherins are also important for creating a physical separation 
of plasma membrane proteins in epithelial and endothelial cells, thus establishing apico-
basal polarity  14, 17, 18. 
Of note, VE-cadherin and N-cadherin expression is mutually regulated in ECs. In the 
absence of VE-cadherin, N-cadherin is expressed and localized at cell-cell contacts. 
However, upon VE-cadherin expression, N-cadherin is downregulated and excluded from 
cell-cell contacts. VE-cadherin/β-catenin association prevents β-catenin nuclear 
translocation and transcriptional activity, thus reducing the expression of N-cadherin which 
is a β-catenin transcriptional target  19. 
Cadherin levels in ECs are not just important for adhesion per se but strongly influence 
EC behaviour. Indeed, both N-cadherin and VE-cadherin expression enhance EC 
proliferation and limit apoptosis. Together with preventing β-catenin nuclear translocation 
and transcriptional activity, the levels of N-cadherin and VE-cadherin correlate with the 
degree of activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway that results 
in the phosphorylation and subsequent inactivation of the transcription factor FoxO1 (also 
known as Forkhead in rhabdomyosarcoma, FKHR), involved in cell growth inhibition and 
induction of apoptotic death  19. 
The importance of VE-cadherin and N-cadherin in ECs is highlighted by the vascular 
phenotype displayed by mice lacking either of these two cadherins. Briefly, N-cadherin 
deletion in ECs results in developmental delay and in defective embryonic and yolk sac 
vasculature. At the ultrastructural level, ECs show signs of apoptosis  20. Similarly, VE-
cadherin-null mice die at E9.5 because of severe vascular defects. Interestingly, VE-
cadherin deficiency does not affect angioblast differentiation to ECs and vasculogenesis in 
mutant embryos occurs normally. However, by E8.5 vascular defects start to be visible in 
VE-cadherin-null embryos with impairment of vascular lumen formation and 
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disconnection between ECs in the yolk sac. Vascular defects become even more severe 
beyond E8.75 when the primitive vascular network needs to undergo sprouting, 
angiogenesis and remodelling. At this point ECs throughout the vasculature become 
progressively disconnected from each other, showing gaps, losing contacts with the 
underlying basement membrane and displaying features of apoptotic cell death  21. Beyond 
E9.25, vessels in VE-cadherin-null embryos regress and collapse causing circulatory 
insufficiency and extensive necrosis. This demonstrates that VE-cadherin expression is 
dispensable during vasculogenesis but it has a central role in the remodelling, expansion 
and maturation of the primitive vascular network. Of note, the majority of vascular defects 
in VE-cadherin-null mice occurs before the onset of blood flow, thus suggesting that the 
lack of VE-cadherin in ECs has profound consequences on EC intracellular signalling as 
well. The apoptotic cell death of ECs observed in VE-cadherin-null embryos is attributed 
to the disruption of a multiprotein complex composed of VE-cadherin, VEGFR2, β-catenin 
and PI3K which is required to respond to VEGF-A survival signal. VE-cadherin/VEGFR2 
partnership is important not only during embryonic development but also in the adult 
organisms, in the regulation of EC quiescence (see below)  22, 23.  
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Figure 3 Schematic representation of endothelial AJs 
Endothelial AJs are composed of proteins of the cadherin family such as VE-cadherin and N-cadherin. VE-
cadherin mediates interaction between neighbouring ECs while N-cadherin mediates interaction between ECs 
and pericytes. Among the numerous cadherin intracellular partners p120, α-catenin, β-catenin and 
plakoglobin regulate cadherin stability at junctions, binding with actin cytoskeleton and intracellular 
signalling. Adapted from Nyqvist et al., 2008. 
 
 
Besides AJs, the other major component of endothelial cell-cell contacts are TJs (also 
called zonula occludens) (Figure 4). These are intercellular junctional complexes present in 
epithelial and endothelial cells which are able to physically seal the plasma membrane of 
two adjacent cells, regulating the passage of cells and solutes through the paracellular 
space  24. While in epithelial cells TJs are the most apical components of the junctional 
complex, in ECs TJs are often intermingled with AJs along the cell cleft. TJs are 
multiprotein structures composed of transmembrane proteins such as claudins, occludin, 
Junctional Adhesion Molecules (JAMs) and membrane-associated proteins such as Zonula 
Occludens (ZO)-1, -2 and -3 and cingulin  25. Claudins exert their main biological function 
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by sealing the membranes of neighbouring cells and are crucial determinants for the fine 
regulation of the paracellular permeability to ions and plasma proteins. They form a large 
family composed of 24 different members in human and mouse, some of which (i.e. 
claudin-1, claudin-3, claudin-5 and claudin-12) are expressed in ECs. Among these only 
claudin-5 shows an EC-restricted expression pattern  26-28. Claudins are 21-28 kDa proteins 
and consist of four transmembrane domains, two extracellular loops, amino- and carboxy-
terminal cytoplasmic domains and a short cytoplasmic turn. Most claudins contain the 
conserved aminoacid motif GLWxxC(8-10 aa)C in the first extracellular loop and a PDZ 
(Post synaptic density protein, Drosophila disc large tumor suppressor and Zonula 
occludens-1 protein) domain-binding motif at the carboxy terminus, which is needed for 
the association with PDZ-containing TJ proteins such as ZO-1, ZO-2 and ZO-3  24. 
Claudins expressed on the same plasma membrane laterally associate with each other to 
form the so-called TJ strands. TJ strands present on adjacent cells are further involved in 
homotypic interactions in order to form “paired” strands and seal the two membranes  29. 
The distinct tightness properties of a given tissue seem to be largely dependent on the 
combination of the claudins composing such stands and on the manner in which they co-
polimerize. A certain claudin family member may associate with identical molecules 
(homophilic interaction) or with other family members (heterophilic interaction)  30. 
Overall, this suggests that TJ strands are usually composed of a "mosaic" of different 
claudins involved in homotypic and heterotypic interactions depending on the claudin 
expression pattern of the tissue  24, 30. 
Besides claudins, other proteins are key components of TJs (Figure 4). Occludin, like 
claudins, is a four-pass transmembrane protein with both N-terminal and C-terminal 
cytoplasmic domains. The carboxy-terminal cytoplasmic region of occludin binds to other 
TJ-associated proteins such as ZO-1, ZO-2 and ZO-3. Occludin-deficient epithelial cells do 
not show any overt abnormality in the morphology and physiology of TJs and mice 
knockout for this protein are viable  24. Tricellulin, instead, is the only known TJ protein 
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that concentrates at the conjunction between three cells. Tricellulin contains four 
transmembrane domains and a carboxy-terminal cytoplasmic domain that shares sequence 
similarity with occludin. Tricellulin knockdown in epithelial cells leads to alteration of 
tricellular TJs and epithelial barrier function  31, 32. Other important TJ proteins such as ZOs 
do not contain any transmembrane region but present PDZ domains that enable them to 
interact with TJ-associated integral membrane proteins. ZO-1, ZO-2 and ZO-3 consist of 
three PDZ domains, a Src Homology (SH)3 domain and a guanylate kinase (GUK) 
domain. The first PDZ domain directly binds to the C-terminus of claudins  33. 
Interestingly, it has been demonstrated that ZO-1 and ZO-2 are indispensable for TJ 
formation in epithelial cells. Umeda and coworkers generated epithelial cells 
simultaneously lacking the expression of ZO-1, ZO-2 and ZO-3 and noticed that these 
cells, despite showing a normal epithelial morphology and AJ protein expression and 
distribution, completely lack TJs. By re-expressing ZO-1 and/or ZO-2 in these cells the 
authors rescued claudin polymerization at TJs and identified the SH3/GUK domain of ZO-
1 as an essential domain for this function  34, 35.  
Epithelial and endothelial TJs also contain proteins of the JAM family. JAM proteins 
belong to the immunoglobulin (Ig) superfamily and have two extracellular N-terminal Ig-
like domains, a transmembrane region and a short cytoplasmic tail harbouring a PDZ-
binding domain. This latter is responsible for the interaction of JAMs with other TJ 
components such as ZO-1 and Afadin-6 (AF-6)  36-38. The JAM family consists of 5 
members, JAM-A, -B and -C being the most studied and JAM-4 and JAM-L the most 
obscure. Every JAM displays its own peculiar pattern of expression. JAM-A is reported to 
be the most widely expressed in endothelial and epithelial tissues of many organs and in 
platelets, erythrocytes and leukocytes. JAM-B, instead, is expressed exclusively by ECs 
while JAM-C is present both in ECs and leukocytes. Much less is known about the 
expression pattern of JAM-4 and JAM-L. Of note, also JAM proteins are engaged in both 
homophilic (i.e. with identical JAM molecules) and heterophilic (i.e. with different JAMs 
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or other unrelated proteins) interactions. JAM-A, JAM-B, JAM-C and JAM-L contain a 
putative dimerization loop in their N-terminal region and are able to localize at cell-cell 
contacts in close proximity with TJ strands. In addition to their role in promoting TJ 
formation in epithelial and endothelial cells, JAMs modulate other important processes 
such as leukocyte adhesion and transmigration through EC monolayers and platelet 
activation  36-38.  
 
                        
 
Figure 4 Schematic representation of endothelial TJs 
Claudins play a central role in the formation of TJ strands between ECs. Other proteins such as JAMs, ZO-1, 
ZO-2 and cingulin take part in the formation of TJs. ZO-1 and ZO-2 bind to claudins cytoplasmic domain 
and are necessary for claudin polymerization at TJs. Adapted from Nyqvist et al., 2008. 
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Intracellular signalling emanating from cell-cell junctions 
 
Junctions between both epithelial and ECs have long been considered simply as 
adhesive structures. However, during the last decades it has been clearly demonstrated that 
a plethora of intracellular signalling pathways is modulated by cell-cell contacts. EC 
junctions exert two major roles: they maintain the integrity of the endothelium and they are 
able to convey intracellular signals which modulate key aspects of EC physiology such as 
cell growth, apoptosis, cell polarity and migration  13, 14, 39. Indeed, intercellular contacts are 
now seen as signalling units that enable ECs to probe the surrounding environment and 
feel their neighbouring cells, thus regulating themselves according to such clues  13. The 
final outcome of junction-triggered signalling pathways is often the regulation of the 
expression of specific target genes with profound consequences on cell behaviour or cell-
cell junctions themselves: contact inhibition versus proliferation, remodelling of cell-cell 
contacts causing epithelial or endothelial to mesenchymal transition for instance. The 
functional link between cell-cell adhesion and the modulation of nuclear activity resides in 
the ability of several junctional proteins to translocate to the nucleus under certain 
conditions and to alter the transcriptional output of the cell.  
Many different proteins are reported to interact with the cytoplasmic tail of cadherins in 
ECs. Among these intracellular partners, α-, β-, γ- and p120-catenin have been reported to 
exert fundamental roles in regulating cadherin behaviour. A key regulator of both cell-cell 
junction stability and gene transcription in ECs is β-catenin. Actually it has been reported 
that the binding of β-catenin to the cytoplasmic tail of classical cadherins starts in the 
endoplasmic reticulum and is required for the correct transport of cadherins through the 
biosynthetic pathway  16. Furthermore β-catenin is a well-known transcriptional co-
activator composed of 12 armadillo repeats that enable it to bind to multiple partners both 
at junctions and in the nucleus. In resting non-stimulated cells the steady state levels of β-
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catenin are kept under control by the activity of the so-called β-catenin destruction 
complex composed of Adenomatous Polyposis Coli (APC), Casein Kinase 1 (CK1), Axin 
and Glycogen Synthase Kinase 3 β (GSK3β). Τhis complex promotes N-terminal β-catenin 
phosphorylation, flagging it for beta-transducin repeat containing protein (βTrCP)-
dependent ubiquitylation and proteasomal degradation. Upon the binding of the Wingless-
related MMTV integration site (Wnt) ligand to Low-density lipoprotein receptor-related 
protein 5 (LRP5)/Frizzled 4 receptors, the β-catenin destruction complex falls apart, β-
catenin accumulates inside the cell and can translocate into the nucleus via mechanisms 
that are still not well understood  40 (Figure 5). Once inside the nucleus, β-catenin binds to 
DNA-bound T-Cell Factor (TCF) transcription factors that recognize the nucleotide 
sequence AGATCAAAGG. In the absence of Wnt stimulation, TCFs bind the 
transcriptional repressor Groucho that keeps Wnt/β-catenin target genes in an "off" state. 
When Wnt ligands are present, nuclear β-catenin accumulates and displaces Groucho 
factors from TCFs, thus promoting Wnt/β-catenin target gene activation  40. Other proteins 
associate to the TCF/β-catenin complex in order to drive gene expression. B-cell 
CLL/lymphoma 9 protein (Bcl9)/Legless and Pygopus, for instance, are key partner of the 
TCF/β-catenin complex in Drosophila melanogaster but knockout studies in mice suggest 
that they seem to be dispensable for Wnt/β-catenin target gene activation in mammals  40. 
Other β-catenin nuclear partners that participate in gene activation are the histone acetyl 
transferase CREB-Binding Protein (CBP) and Brahma-related gene-1 (Brg-1)  40, 41 (Figure 
5). Different cellular pools of β-catenin, characterized by different features, exist. While 
the half life of the signalling pool of β-catenin is in the order of minutes, the pool residing 
at AJs is considered to be highly stable and less dynamic  18, 40, 42, 43. Moreover, binding of 
β-catenin to cadherins limits cell growth by preventing β-catenin-dependent transcription 
of two genes involved in cell cycle progression like cyclin D1 and Myc  14. Another way 
through which cadherins restrain cell proliferation is mediated by the induction of cell 
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cycle arrest in G1 phase by the dephosphorylation of Retinoblastoma protein (pRb) and the 
increase in cyclin-D1-dependent kinase inhibitor p27KIP1 levels  44. 
 
         
 
 
 
 
 
 
 
Figure 5 Schematic representation of the Wnt/β-catenin pathway 
Top panel: in the absence of Wnt ligands β-catenin is degraded by the β-catenin destruction complex (left). 
Wnt stimulation promotes the disassembly of the β-catenin destruction complex, thus leading to β-catenin 
accumulation inside the cell (right). Lower panel: in the presence of Wnt, β-catenin accumulates in the 
nuclus and displaces the transcriptional repressor Groucho to promote the activation of Wnt-target genes. 
Adapted from Clevers and Nusse, 2010. 
 
Like β-catenin, other proteins belonging to the catenin family, such as p120 and γ-
catenin, have functions both at cell-cell contacts and in the nucleus. p120-catenin, for 
instance, binds the cytoplasmic tail of classical cadherins stabilizing them at cell-cell 
contacts by preventing their internalisation and recycling. In addition, p120-catenin has 
been reported to translocate to the nucleus where it displaces the transcriptional repressor 
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Kaiso from target gene promoters  18, 43. γ-catenin (also known as plakoglobin) has been 
reported to localise both at cell-cell contacts and nuclei and to exert a role in the regulation 
of Wnt/β-catenin pathway. In addition, it has also been found that plakoglobin is 
insufficient per se for TCF-dependent transcriptional activation under Wnt-3a stimulation  
43, 45. 
ZO-1-associated nucleic acid binding protein (ZONAB) is a Y-box transcription factor 
that is reported to localize both at TJs and in the nucleus and to promote cell proliferation. 
ZONAB binds to the SH3 domain of ZO-1 and this interaction is required for sequestering 
ZONAB at the plasma membrane and restraining its nuclear localization, thus reducing cell 
proliferation. Interestingly, in Madin-Darby Canine Kidney MDCK cells ZO-1 and 
ZONAB expression are inversely regulated by cell density: ZO-1 expression rises with 
increasing culture density while ZONAB shows the opposite trend of regulation. Taken 
together, these data point to a role for these TJ proteins in contact-dependent inhibition of 
cell growth  43, 46.  
Cell-cell junctions are able to influence cell cycle progression and intracellular 
signalling also because junctional components such as cadherins bind to growth factor 
receptors like VEGFR2. When ECs are confluent, they are considered to be in a quiescent 
state, however they are able to readily re-enter the cell cycle or begin to migrate in 
response to stimuli or when endothelial junctions are dismantled. In accordance with this, 
it has been demonstrated that when ECs are confluent, VE-cadherin clusters at AJs and 
forms a complex with VEGFR2, promoting its dephosphorylation by Density Enhanced 
Protein-1 (DEP1). These events lead to the inhibition of cell growth while promoting cell 
survival via AKT pathway activation. In sparse ECs, on the other hand, VE-
cadherin/VEGFR2 association is reduced and VEGFR2 signals mainly to promote 
proliferation through the activation of the Extracellular-signal-Regulated Kinases/Mitogen-
Activated Protein Kinase (ERK/MAPK) pathway.  
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The expression and clustering of VE-cadherin at endothelial cell-cell junctions is of 
central importance for mediating pro-survival signals in ECs. This is accomplished through 
the formation of a multiprotein complex composed of VE-cadherin/VEGFR-2/β-
catenin/PI3K that, upon VEGF-A stimulation, promotes AKT activation and 
phosphorylation. Aside from VEGF-dependent activation in ECs, AKT can be activated 
also by VE-cadherin clustering at AJs, thus leading to the phosphorylation and inactivation 
of FoxO transcription factors  19, 21, 26, 47, 47 (Figure 6).  
FoxO transcription factors are involved in the development, remodelling and 
maintenance of the vasculature. Three different FoxO proteins are expressed in ECs: 
FoxO1, FoxO3a and FoxO4. All these transcription factors are similarly regulated by the 
AKT pathway. FoxO1 is expressed at highest levels in ECs and it undergoes AKT-
dependent phosphorylation on three residues: Thr 24, Ser 256 and Ser 319  47, 48. These 
phosphorylation events negatively regulate FoxO1 function by altering its capacity to bind 
the DNA and promoting its nuclear exclusion  47 (Figure 6). 
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Figure 6 AKT-dependent regulation of FoxO1  
Once activated by several stimuli, PI3K phosphorylates AKT on Ser 473 and Thr 308. Active 
(phosphorylated) AKT traslocates to the nucleus where it phosphorylates and inactivates FoxO1 transcription 
factor  47. 
 
 
In line with its high expression in ECs, FoxO1 knockout mice show a vascular 
phenotype, while animals devoid of FoxO3a and FoxO4 display only a modest phenotype, 
if any  49. More in detail, FoxO1-/- mice at E9.5 show severe vascular defects in both 
extraembryonic and embryonic tissues. Yolk sacs lack well-developed blood vessels, heart 
looping is retarded and there are major defects in the development of dorsal aorta, 
intersomitic vessels and of the vasculature of the head. All these defects are in line with the 
growth retardation shown by FoxO1-/- mice.  Eventually these mice do not survive beyond 
E10.5. These findings are in agreement with the reported strong and widespread FoxO1 
expression in the developing vasculature in the embryo and suggest that FoxO1 activity is 
dispensable for vasculogenesis while seems to be crucial for the subsequent steps of 
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angiogenesis and remodelling of the primitive vascular network. Furthermore, deregulated 
connexin 37, connexin 40 and Ephrin B2 expression, together with mild defects in VEGF 
response have been reported to occurr in FoxO1-/- ECs  50. Interestingly, Potente et al. 
demonstrated an antiangiogenic role of FoxO1 in ECs in vitro. The authors showed that 
FoxO1 and FoxO3a overexpression in ECs strongly impairs EC tube formation and VEGF-
mediated EC migration. Conversely, FoxO1 or FoxO3a knockdown results in an increase 
in EC sprouting assessed by spheroid assay. In addition, it has been shown that FoxO1 and 
FoxO3a regulate the expression of several important genes involved in angiogenesis and 
vascular remodelling. Briefly, upon FoxO1 knockdown endothelial Nitric Oxyde Synthase 
(eNOS), E-twenty six (ETS) domain protein Elk3 and the apoptosis inhibitor survivin are 
upregulated, while Angiopoietin-2 (Ang-2) is downregulated  51. In agreement with these 
data, Daly and coworkers found that ECs treated with Angiopoietin-1 (Ang-1) undergo 
strong AKT activation with subsequent FoxO1 phosphorylation and inactivation. 
Conversely, FoxO1 overexpression led to a strong induction of genes linked to vascular 
remodelling, extracellular matrix reorganization and cell migration such as Ang-2, decorin, 
lumican, collagen type-3 and fibulin-5  52. Given the role of FoxO1 as an inhibitor of eNOS 
and as an activator of Ang-2, we can envision that FoxO1 is a transcription factor 
promoting vascular remodelling and vessel destabilisation  47, 51, 52.  
 
 
 
The importance of vascular stabilisation 
 
In order to fulfill the metabolic requirements of a given tissue, sprouting angiogenesis is 
only the first step of a much more complex process. Indeed, once new vessels are formed, 
they need to undergo a maturation or stabilisation phase in order to become fully 
competent and functional. Vascular maturation occurs both at the EC level through the 
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deposition of new basement membrane, the recruitment of mural cells, the reduction of EC 
proliferation and the sustained endothelial cell-cell junction formation but also, in a 
broader sense, at the network level. This means that new vessels must be organised into a 
hierarchically ordered network that is able to cope with the metabolic requirements of the 
perfused tissue  53, 54.  
A fundamental feature of vessel maturation is the recruitment of mural cells (pericytes 
and smooth muscle cells). Pericytes are stellate-shaped cells that wrap the endothelium 
providing mechanical stability to capillaries. In addition, thanks to their position around 
endothelial cell-cell junctions, pericytes cover gaps between ECs and regulate barrier 
function  54. Pericytes establish direct cell-cell contacts with ECs in capillaries and 
immature vessels via N-cadherin expressed on both ECs and pericytes themselves. Arteries 
and veins, instead, are covered by a layer of extracellular matrix and by vascular smooth 
muscle cells. Recruitment of mural cells is controlled by platelet-derived growth factor 
receptor β (PDGFR-β) signalling. Endothelial PDGF-B signals to PDGFR-β expressed by 
mural cells, stimulating their migration and proliferation. Inactivation of either Pdgfb or 
Pdgfrb induces pericyte deficiency, vascular dysfunction, micro aneurysm formation and 
bleeding  55, 56.  
As already mentioned, the deposition and remodelling of the extracellular matrix and 
basal membrane surrounding blood vessels has an important role in regulating 
neoangiogenesis as well as vessel stabilisation  3, 6, 57. It has been recently demonstrated 
that the proteolytic processing of extracellular matrix components can promote or inihibit 
angiogenesis in a context-dependent manner. For instance, MMP or plasmin activity can 
promote angiogenesis and EC migration by multiple mechanisms such as decreasing the 
stiffness and density of extracellular matrix and by releasing matrix-bound proangiogenic 
molecules such as VEGF and Fibroblast Growth Factor-2 (FGF-2). On the contrary, by 
cleaving extracellular matrix proteins, proteases can create proteolytic fragments that have 
anti-angiogenic properties. For example, endostatin, an anti-angiogenic factor, is generated 
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by proteolytic processing of collagen XVIII by elastase or other proteases  57, 58. Many 
publications highlight also an important role for extracellular matrix proteins in vessel 
stabilisation. Of note, mice lacking fibronectin die during embryogenesis due to 
cardiovascular defects and alterations in vessel lumen formation and maintenance  57, 59, 60. 
Furthermore, the genetic inactivation of collagen I, collagen III and fibrillin in mice leads 
to vascular stability defects and blood vessel rupture  61, 62. 
Endothelial cell-cell junction formation and strengthening is another key aspect of 
vascular stabilisation. Intercellular contacts stabilise new vessel through different 
mechanisms. First, when ECs come into contact, new junctions are formed through 
homophilic interaction of cell adhesion molecules such as cadherins. Subsequently, AJ 
formation promotes the correct organization of TJs and ECs become fully competent for a 
precise control of vessel permeability  14, 26. Moreover, as already discussed, cell-cell 
contact formation has a crucial role in limiting EC growth and apoptosis thus leading to the 
quiescent state of ECs observed in resting and stabilised vessels  14, 23.   
In the adult organism, the turnover of ECs and extracellular matrix surrounding blood 
vessels is considered to be very low. In healthy conditions, ECs are in a quiescent state and 
the vasculature is stabilised. Angiogenesis in the adult is generally confined to pregnancy, 
menstrual cycle and wound healing processes  6, 55, 63. In contrast, new blood vessel 
formation acquires a central importance in many pathological conditions such as chronic 
inflammation, stroke and cancer. As discussed in detail below, many aspects and features 
of blood vessels are altered during tumour angiogenesis. These anomalies are present in a 
wide range of solid tumour types both in mice and humans and can vary among different 
neoplastic tissues  6. Tumour vessels are tortuous, follow a serpentine course, branch 
irregularly in a chaotic network of tangles (Figure 7). Inside the same tumour mass, vessels 
exhibit also a striking heterogeneity ranging from capillary-like to big, leaky, thin-walled, 
pericyte-depleted fenestrated sinusoids, or glomeruloid vessels and other vascular 
malformations  6, 63, 64. Tumours have developed several different strategies to attract and 
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co-opt blood vessels in order to sustain their growth. New blood vessel sprouting from pre-
existing ones is the most obvious way that tumour cell exploit to gain new vessels but 
increasing evidence in the literature suggests that other mechanisms could occur, at least in 
some kinds of tumours: 1) the recruitment of bone marrow-derived endothelial progenitor 
cells (EPCs) to newly forming vessels, 2) intussusception, defined as the splitting of a pre-
existing vessel into two (also known as splitting angiogenesis), 3) vessel co-option, defined 
as the growth of cancer cells in close proximity to pre-existing vessels, 4) vascular 
mimicry, meaning that cancer cells get incorporated into the vessel wall, thus creating 
"mosaic vessels", 5) tumour stem cell to EC differentiation  6, 53, 63, 64. In tumours, vessel 
diameters are often uneven given the different compression of tumour cells and stroma on 
the vessels in the different areas of the neoplastic mass. Most importantly, in contrast with 
normal vessels, which are lined by a monolayer of quiescent ECs and displaying a clear 
apical-basal polarity, tumour endothelial cells are often hyperactivated and display loose 
intercellular contacts. In this context ECs have an altered cell polarity, detach from the 
basement membrane and might eventually die, therefore creating an easy route for cancer 
cells to enter the circulation and cause peripheral metastases (Figure 7). ECs lining tumour 
vessels often undergo endothelial-to-mesenchymal transition and move away from their 
resident site, thus leaving behind empty sleeves of EC-devoid matrix channels (also known 
as string vessels). Pericyte abnormalities add up to EC defects in tumour vessels. In most 
cancers, vessels are poorly covered by pericytes, which are activated and loosely 
associated to ECs  54 (Figure 7). Because of the continuous remodelling occurring in 
tumour vessels, also the basement membrane is often altered and loosely associated to 
ECs. It is not uncommon to find vessels no longer surrounded by a basement membrane, 
very fragile and prone to rupture. Conversely, in some specific tumour contexts, vascular 
basement membrane could undergo opposite alterations. In hepatocellular carcinoma, for 
instance, tumour vessels deposit an ectopic basement membrane, not present in the healthy 
tissue  54, 64. All these abnormalities profoundly alter vascular functionality. Indeed, tumour 
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blood flow is chaotic and even stagnant in several areas of the tumour mass. As tumour 
vessels are leaky, they cannot maintain pressure gradients across their walls. Normally, 
fluid pressure inside healthy vessels is higher than in the surrounding tissue. However, 
owing to the leakiness of tumour vessels, fluids and plasma proteins escape from the vessel 
lumen and accumulate in the interstitial space. These events result in an uncontrolled 
increase of the extravascular oncotic pressure dragging further liquid into the interstitium, 
thus raising even more the interstitial fluid pressure (IFP) and producing tissue swelling 
(oedema)  64. These uneven flow patterns, together with the unnatural pressure gradient, not 
only create an obstacle to the transport of oxygen and nutrients, but also dramatically 
reduce the delivery of drugs to cancer cells and, consequently, their effectiveness  54. The 
raised intratumoural IFP reduces the hydrostatic pressure gradient between the 
intravascular and extravascular compartments such that the two essentially equilibrate. In 
addition, the mechanical stress from the solid mass of proliferative cancer cells is able to 
collapse tumour vessels, closing their lumen through compressive forces.  
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Figure 7 Tumour vessels are structurally and functionally abnormal 
(a) In healthy tissues vessels display a hierarchical organization, are lined with a continuous monolayer of 
quiescent ECs and are covered by pericytes and by a homogeneous basement membrane (BM). In this way 
the vasculature ensures an optimal delivery of oxygen and nutrients. 
(b) In tumors, vessels are leaky and tortuous. In this context, there are often gaps between ECs, basement 
membrane is discontinuous and pericytes are detached. These features lead to poor perfusion of the tumor 
mass with ensuing hypoxia, reduced drug delivery and oedema  54. 
 
Rapidly growing tumour cells are in continuous demand for oxygen and nutrients. 
However, the non-productive form of angiogenesis which arises fails to meet the needs of 
the tumour mass. While in physiological conditions proangiogenic factors promote new 
vessel growth in a controlled manner and anti-angiogenic molecules tightly limit this 
process, in the tumour microenvironment proangiogenic molecules are produced in large 
excess by tumour and stromal cells. This profoundly unbalanced microenvironment is 
thought to be the cause of the discussed vascular abnormalities. Given the uneven blood 
flow and the suboptimal delivery of oxygen and nutrients inside the tumour mass, cancer 
cells often experience severe hypoxic conditions and acidosis that can alter their gene 
expression profile, making them more aggressive and more prone to metastasise  64.  
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In the last decade, research has been focusing on the identification of possible 
approaches to restore the imbalance between pro and antiangiogenic factors in tumours, 
aimed at inducing a reversion of tumour vessels from an altered towards a more normal 
phenotype, a process known as "vascular normalisation"  64. Unlike antiangiogenic 
therapies, consisting in the destruction of tumour vasculature, vessel normalisation aims at 
the use of pharmacological and/or genetic approaches to revert the gross morphological 
and functional abnormalities of such vessels. Vascular normalisation might occur through 
different mechanisms such as increasing the homogeneity of vascular density, restoring 
vessel hierarchy within the tumour vascular bed and improving endothelial cell-cell 
junction organization and perivascular cell coverage in order to recover the control of 
vessel permeability  54, 63, 64. Although tumour vessels may never become completely 
"normal", these changes would yield a more even distribution of blood flow with a 
subsequent reduction of tissue hypoxia and acidosis. This would also impede cancer cell 
metastatic behaviour and improve drug delivery. 
Traditionally, given the widely recognized importance of VEGF in promoting tumour 
angiogenesis, many groups aimed at blocking VEGF signalling in order to dramatically 
reduce vessel growth with the ultimate goal of starving tumour cells. Among the numerous 
tools generated to block VEGF signalling it is worth to mention Bevacizumab, an anti-
human VEGF antibody; Aflibercept (also known as VEGF-Trap) that binds VEGF-A, 
VEGF-B and Placental-derived Growth Factor (PlGF); DC101, an antibody recognizing 
VEGFR2; and several small molecules that inhibit VEGFR2 tyrosine kinase activity. 
Despite the promising results obtained in pre-clinical models, Bevacizumab as 
monotherapy failed to induce significant benefits to patients in several phase III clinical 
trials while it improves the progression-free survival and overall survival when given in 
combination with traditional chemotherapy  54, 64, 65 
Several studies have pointed out the existence of a "time window" in which the 
pharmacological induction of vascular normalisation is effective. Therefore, vascular 
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normalisation seems to be a transient phenomenon typically starting 1 or 2 days after the 
beginning of the therapy and followed by an eventual "closure" of the normalisation 
window, when features of normalisation are lost. This is due either to an excessive dose of 
the antiangiogenic drug or to the development of resistence via the activation of other 
proangiogenic pathways. Importantly, it has been shown that cancer cells are more 
vulnerable to cytotoxic therapies specifically during the normalisation window  6, 63, 64. 
Taken together, these findings point out that we still need an in depth understanding of the 
mechanisms that govern vascular stabilisation. By exploiting these findings we will be able 
to design new therapies aimed at extending the so called "vascular normalisation window" 
to improve cancer treatment.  
 
 
 
Claudin-5, VE-PTP and vWf: three vascular stability genes 
 
 
 
Many different genes have been reported to have a role in vascular stabilisation but only 
some of them are expressed in an endothelial-restricted manner. Among these, we focused 
on claudin-5, Vascular Endothelial Protein Tyrosine Phosphatase, VE-PTP (also known as 
Protein Tyrosine Phosphatase Receptor Type B, Ptprb) and von Willebrand Factor (vWf), 
because, as extensively explored in the following chapter, they seemed, from previous 
observations, to be regulated in the same fashion. Remarkably these proteins, although 
exerting very different functions and showing different subcellular localizations, play an 
important  role in the establishment of a stabilised vessel phenotype. 
Claudin-5 is the only member of the claudin family of genes that shows an endothelial-
restricted expression pattern. Evidence in the literature points to a crucial role for claudin-5 
in vascular stabilisation. VE-cadherin clustering at the plasma membrane has been shown 
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to upregulate claudin-5 expression through the activation of the PI3K/AKT pathway 
leading to the phosphorylation and subsequent cytoplasmic relocalization of FoxO1 and to 
the inhibition of its transcriptional activity. When VE-cadherin is absent or not clustered at 
junctions, FoxO1 and β-catenin bind to claudin-5 gene promoter inhibiting its expression. 
VE-cadherin clustering, through PI3K/AKT activation and the sequestration of β-catenin at 
the plasma membrane, relieves FoxO1/β-catenin-mediated inhibition of claudin-5 
transcription and promotes the correct organization of TJs and permeability control  26. In 
addition, these data confirm that an interplay and a hierarchy exist between AJs and TJs. 
Indeed, other reports demonstrated that AJ formation precedes and promotes TJ formation 
and that interfering with AJ establishment leads to TJ impairment  14, 66. Junctional 
maturation in ECs is of key importance for vessel stabilisation and is strictly required to 
create morphologically and functionally competent blood vessels  13, 53, 54. The importance 
of claudin-5 expression in ECs has been further demonstrated by the generation of claudin-
5 knockout mice. These mice show normal embryo development and are born alive but die 
within 10 hours after birth. Microscopic evaluation of brain vasculature at E9.5 and E18.5 
shows no overt abnormalities, no signs of oedema or bleeding. Surprisingly, by electron 
microscopy it is still possible to appreciate TJs of normal appearance between brain ECs. 
However, brain vessels display a size-selective loosening in the absence of claudin-5. The 
authors report that the blood-brain barrier of  claudin-5-/- mice is permeable to molecules 
weighing less than 800 Da, while bigger tracers are retained inside the vessels  67, 68. 
VE-PTP is an endothelial-specific gene encoding a protein tyrosine phosphatase 
involved in the regulation of crucial players in vascular development and function such as 
VE-cadherin, angiopoietin receptor Tie2, VEGFR-2 and plakoglobin. Mouse VE-PTP 
protein is composed of 17 extracellular fibronectin type III-like repeats (FN3), one 
transmembrane domain and one intracellular phosphatase domain (PTP). The importance 
of VE-PTP in the establishment of a correct vascular network has been highlighted by the 
generation of VE-PTP knockout mice and zebrafish morphants. VE-PTP-/- mice die around 
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E10 most probably because of a plethora of severe vascular and cardiac defects. For 
instance, these mutants show yolk sacs without hierarchically organized vessels, often lack 
intersomitic vessels and display dilated pericardial cavity and incomplete turning of the 
heart. These vascular alterations suggest that VE-PTP-/- mice can not undergo a productive 
remodelling phase of the primitive vascular network, while the vasculogenesis phase 
seems to be unaffected  69, 70. As expected, VE-PTP expression is restricted to blood vessels 
and in particular the highest expression levels are reported to be in arteries. Knockdown 
experiments in zebrafish using morpholino injection confirmed the findings obtained with 
VE-PTP-/- mice. Also in zebrafish zve-ptp shows a widespread expression in the developing 
vascular system of embryos and early larvae. Morpholinos blocking mRNA translation and 
splice-blocking morpholinos altering the extracellular domain of the protein, without 
affecting the intracellular catalytic domain, cause vascular fragility and other defects. 
These comprise intersomitic vessels with anomalous branching or truncations, blood stasis 
in the caudal region of the axial vein and in some cases leakage of blood out the vessel 
wall. Of note, all zve-ptp morphants show strong ultrastructural alterations of endothelial 
cell-cell junctions and an increase in the number of ECs extending filopodia  71. VE-PTP is 
reported to interact and dephosphorylate angiopoietin receptor Tie2, thus modulating its 
activity  72, 73. More in details, Winderlich et al. demonstrated that treatment of allantois 
explants or ECs with anti-VE-PTP antibodies leads to the specific dissociation of VE-PTP 
from Tie2, resulting in an increase of Tie2 phosphorylation that mimics Ang-1 stimulation. 
Interestingly, the authors found that upon Ang-1 stimulation Tie2 phosphorylation 
increases but at the same time Tie2 associates more with VE-PTP, establishing a negative 
feedback loop that controls Tie2 signalling. ECs either stimulated with Ang-1 or treated 
with anti-VE-PTP antibodies undergo an increase in their proliferation rate that is mediated 
by ERK1/2 and AKT pathway activation  73. Saharinen and coworkers demonstrated that in 
confluent ECs Ang-1 stimulation leads to Tie2 translocation to cell-cell contacts where it 
binds VE-PTP and Tie1. In this context Tie2 preferentially signals through AKT which 
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phosphorylates and activates eNOS, thus leading to vascular stabilisation and reducing 
monolayer permeability  74. VE-PTP has been also reported to interact with VE-cadherin 
and to reduce VEGFR2-dependent VE-cadherin phosphorylation, thus increasing VE-
cadherin-mediated barrier integrity  75. In agreement with these findings, Nottebaum et al. 
reported that VE-PTP interacts with VE-cadherin at cell-cell contacts and that VE-PTP 
expression levels increase with increasing EC confluence, along with its interaction with 
VE-cadherin. Treatment of ECs with siRNAs targeting VE-PTP causes a significant 
increase in EC permeability and neutrophil transendothelial transmigration  76. Very 
recently it has been demonstrated that VE-PTP is also able to modulate VEGFR-2 activity 
in a Tie2-dependent manner. Consistently with its role in vascular stabilisation, the authors 
demonstrated that sprouts arising from VE-PTP-/- embryoid bodies show much less pericyte 
coverage compared to WT sprouts. Moreover, mutant sprouts display also altered 
apical/luminal polarity as assessed by the distribution of podocalyxin and moesin markers 
and strikingly VE-PTP-/- sprouts often do not contain any lumen. The authors propose a 
model through which Tie2 mediates the suppression of VEGFR-2 activity by promoting 
the formation of a multiprotein complex with VE-PTP in order to create functional blood 
vessels. This is of particular interest in pathological contexts where an excess of VEGF or 
a deregulated expression of VE-PTP could profoundly alter EC polarization and lead to the 
formation of poorly functional vessels  10. All these results point to a stabilizing function 
for VE-PTP on blood vasculature. 
VWf is a large multimeric glycoprotein with crucial roles in haemostasis, platelet 
aggregation and transportation of the pro-coagulant Factor VIII (FVIII). Recently this 
molecule has been involved in regulating angiogenesis and vessel stabilisation  77-79. VWf 
is produced by ECs and megakaryocytes as a precursor (pro-vWf) consisting of 2813 
aminoacids that include a 22 aminoacid signal peptide, a 741 aminoacid propeptide and a 
2050 aminoacid mature vWf subunit. Pro-vWf needs to undergo a series of subsequent 
modifications along with its transport through the secretory pathway in order to give rise to 
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the mature vWf protein. In the endoplasmic reticulum pro-vWf undergoes dimerization via 
disulphide bond generation and N-linked glycosylation, then in the Golgi apparatus it is 
further processed with O-linked glycosylation and processing of the N-linked carbohydrate 
side-chains  77-79. Eventually, in the trans-Golgi network pro-vWf is subjected to 
endoproteolytic cleavage and dimers are disulphide-linked in multimers. At this point, 
mature vWf protein can undergo either a constitutive secretion, meaning that the protein is 
released as soon as it is synthesized by the cell as dimers or small multimers, otherwise it 
can be stored in rod-shaped intracellular organelles called Weibel-Palade bodies in ECs 
and α-granules in megakaryocytes and platelets. Once vWf is stored in these intracellular 
organelles, it is secreted as high-molecular-weight multimers together with its propeptide 
in a tightly regulated manner following stimuli such as thrombin, histamine and mediators 
of inflammation such as Tumour Necrosis Factor-α (TNF-α), Interleukin-8 (IL-8) and IL-
6. In circulating platelets only the regulated secretion occurs, so the vast majority of 
circulating vWf protein comes from ECs that release it both in the vessel lumen and in the 
subendothelial matrix. VWf protein harbours several functional domains that are important 
for its functions: A1 domain is required for vWf interaction with the platelet receptor 
glycoprotein GPIbα, A3 domain binds to collagen, C1 domain contains the RGD sequence 
recognized by the β3 integrins (αΙΙbβ3 and αvβ3) and the D'-D3 domains bind FVIII. Von 
Willebrand disease (VWD) is a bleeding disorder characterized by either a quantitative 
deficit in vWf production (type 1 and type 3 VWD) or by the production of dysfunctional 
vWf protein (type 2 VWD)  80. Very interestingly, Starke et al. recently demonstrated an 
unprecedented role for vWf in restraining angiogenesis by inhibiting the function  of 
several important molecules in ECs such as VEGFR2, Ang-2 and integrin αvβ3, the most 
characterized endothelial receptor for vWf. The authors found that ECs taken from patients 
affected from von Willebrand disease or wild type (WT) ECs knockdown for vWf show an 
increase in tube formation and in VEGF-dependent EC migration. Moreover knockdown 
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of vWf results in the concomitant downregulation of αvβ3 integrin both at the 
transcriptional level and via protein internalisation. Weibel-Palade bodies do not store only 
vWf but also other important regulators of angiogenesis and vessel stability such as Ang-2. 
Most importantly, vWf–knockdown ECs show increased levels of Ang-2 release compared 
to control cells. These data are of particular interest given that Ang-2 is a major player in 
vessel destabilisation and remodelling and it unravels an unprecedented role for vWf in 
promoting vessel stabilisation. In agreement with these findings, it has also been 
demonstrated that vWf-deficient mice show an increase in the vascular infiltration in 
subcutaneous Matrigel plugs compared to WT mice  81. Altogether these observations 
clearly show vWf involvement in regulating the quiescent phenotype of stabilised 
vasculature. 
 
 
 
Polycomb Group proteins and transcription regulation  
 
Cells continuously adapt their transcriptional output depending on their needs and on 
the stimuli coming from the surrounding environment, both in vitro and in vivo in living 
organisms. Recently, it has been shown that genes encoding important developmental 
transcription factors are marked with specific histone modifications named "bivalent 
domains" that consist of broad regions harbouring both trimethylation of lysine 27 on 
histone H3 (H3K27me3), a well-established histone mark leading to gene repression, and 
trimethylation of lysine 4 on histone H3 (H3K4me3), a marker of active gene transcription  
82. In embryonic stem (ES) cells, the developmental genes marked by bivalent domains are 
usually expressed at low levels and these histone modifications are thought to be required 
for keeping these genes poised for activation and ready to be turned on when cells undergo 
differentiation. When this occurs, bivalent domains are resolved in either H3K27me3-rich 
  44 
regions or H3K4me3-rich regions and this determines the activation status of the gene  82, 
83.  
Polycomb Group (PcG) and Trithorax Group (TrxG) proteins are the two families of 
epigenetic regulators of transcription that catalyse the H3K27me3 and the H3K4me3 
histone marks, respectively. Both PcG and TrxG proteins were first described in 
Drosophila melanogaster as regulators of Homeobox (HOX) gene expression and body 
segmentation and are very well conserved from plants to vertebrates and mammals, thus 
suggesting their crucial role in the regulation of gene expression 86, 87, 102. PcG proteins 
operate through two different Polycomb Repressive Complexes (PRC) made up of 
different subunits and harbouring different functions (Figure 8). Both PRC1 and PRC2 
complexes have core subunits, i.e. molecules that are invariably present in the complex and 
accessory ones which bind the complex only in certain contexts. Not surprisingly, these 
accessory subunits seem to be involved in finely regulating the activities of PRC 
complexes and the way they are targeted to genomic loci  84-86. Core subunits of the PRC1 
complex are B lymphoma Mo-MLV Insertion region 1 (Bmi1), Really interesting new 
gene 1B (Ring1B), Polyhomeotic protein 1 (Phc1) and Chromobox protein homolog 4 
(Cbx4).  The PRC2 complex contains Enhancer of Zeste Homologue 2 (Ezh2), Suppressor 
of Zeste 12 (Suz12) and Embryonic Ectoderm Development (Eed) as core subunits. The 
principal function of the PRC2 complex is to catalyze H3K27 trimethylation, while PRC1 
complex has the ability to ubiquitylate lysine 119 on histone H2A (H2AK119Ub1), 
another repressive histone mark  84, 86 (Figure 8). PRC complexes are classically thought to 
act sequentially on the chromatin. First, PRC2 complex is recruited to the target gene and 
deposits H3K27me3. Subsequently, PRC1 complex recognizes the H3K27me3 mark and 
deposits H2AK119Ub1  86, 87. Through this mechanism PcG proteins are believed to 
restrain RNA Polymerase II (RNA Pol II) initiation and elongation of transcription and to 
compact chromatin structure. However, a clear picture of how PcG proteins repress their 
target genes is still missing  87.  
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More in details, the PRC2 complex is able to perform the di-/tri methylation H3K27 
thanks to its catalytically active subunit, Ezh2, which bears a Su(var)3-9, Enhancer of 
Zeste, Trithorax (SET) domain. Of note, Ezh2 protein per se is not functional and requires 
the association with at least Suz12 and Eed in order to work efficiently  88. Suz12 is another 
crucial member of the PRC2 complex. In cells lacking Suz12, the PRC2 can not assemble 
and H3K27me3 levels are strongly impaired  89. Eed subunit of PRC2 complex has the 
ability to recognize the H3K27me3 histone mark thanks to its donut-like β-propeller 
structure. This interaction boosts the activity of the PRC2 complex itself by targeting it 
where H3K27me3 is already present. This positive feedback loop helps to localize PRC2 
activity only to certain regions of the chromatin and to maintain H3K27me3 levels during 
cell cycle progression  90, 91.  
 
         
Figure 8 The coordinated activities of PRC1 and PRC2 
PcG protein recruitment is still obscure. PRC binding to TFs may mediate cell type-specific PcG protein 
targeting to chromatin. Once bound to the DNA, PRC2 mediates the deposition of H3K27me3 repressive 
histone mark that can be recognized by Cbx-containing PRC1. Then, PRC1 deposits H2AK119Ub1 and the 
nearby gene is switched off. Adapted from Morey and Helin, 2010. 
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The activity of the PRC2 complex can be modulated by changing the core subunits 
composition, by the binding of accessory proteins and also by post-translational 
modifications. For instance, Ezh2 subunit in some instances can be interchanged with Ezh1  
92 and multiple Eed isoforms can take part to the formation of the complex  88. In addition, 
recent publications demonstrated that several accessory subunits take part in the formation 
of the PRC2 complex and in modulating its activity and targeting to genomic loci. The 
Polycomb-like (Pcl) proteins are a family of cofactors that modulate PRC2 activity. Pcl 
proteins have been reported to stimulate the capacity of PRC2 complex to convert the 
K27me2 to K27me3 and to increase PRC2 levels at target chromatin sites  93, 94. Another 
recently discovered PRC2 accessory protein is Jumonji- and AT-rich interaction domain 
(ARID)-domain-containing protein (Jarid)2, an enzymatically inactive member of the 
Jumonji (Jmj) family of histone demethylase that contains also a DNA-binding domain. 
Jarid2 binding to chromatin shows a significant overlap with Suz12 and H3K27me3 and 
Jarid2 knockdown strongly reduces PcG protein binding to target genes  95. Moreover, 
local chromatin histone modifications related to active transcription, such as H3K4me3 
and di- or tri-methylation of lysine 36 of histone H3 (H3K36me2/me3) can influence the 
activity of the PRC2 complex  96. H3K4me3 is usually found near the promoter of the 
transcribed gene, while H3K36me2/me3 accumulate in gene bodies and towards the 3' end 
of the coding sequence  97. Interestingly, it has been recently demonstrated that the 
presence of either H3K4me3 or H3K36me2/me3 inhibits PRC2 function in cis via 
allosteric modulation of the PRC2 complex that involves Suz12 subunit. These findings 
suggest that PRC2 complex modulates its own activity depending on the histone 
modifications which are already present in the genomic context  87, 96.  
Recent publications suggest that PRC1 complex exists in forms containing or not Cbx 
proteins. The presence or absence of Cbx proteins influences PRC1 genome occupancy 
and function. Indeed, Cbx-containing PRC1 complex tends to colocalise with H3K27me3 
while Cbx-lacking PRC1 complex does not require the interaction with H3K27me3 to bind 
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to chromatin  98, 99. Taken together, these recent findings challenge the proposed 
dependence of PRC1 on PRC2 function for being targeted to chromatin.  
One of the most active areas of research about PcG proteins deals with understanding 
how these are recruited to the target genes. In Drosophila melanogaster the existence of 
DNA sequences able to recruit PcG proteins to chromatin has been clearly demonstrated. 
These are called Polycomb Response Elements (PREs): clusters of DNA binding sites for 
known PcG protein-recruting factors. In mammals, instead, very little is known about PcG 
protein recruitment. Many proteins have been proposed as putative PcG-recruiters. Yin and 
Yang 1 (Yy1) was shown to modulate Ezh2 binding to the chromatin but chromatin 
immunoprecipitation-sequencing (ChIP-seq) data show only a limited overlap between 
PRC2 and Yy1 genome occupancy. Oct4 has also been proposed as a PcG recruiter given 
that its knockdown in ES cells reduces both PRC1 and PRC2 chromatin occupancy. 
Interestingly, 97% of PRC2 ChIP-seq peaks in ES cells overlap with CG-rich regions, thus 
pointing to a possible role for CpG islands in PcG proteins recruitment. The transcription 
factor Snail1 has been shown to bind PcG proteins and to target them to E-cadherin 
promoter in order to repress it. PRC2 component knockdown impairs Snail1 ability to 
repress E-cadherin expression  100. Furthermore, long non coding RNAs (lncRNAs) have 
been shown to play a role in targeting PRCs to genomic loci  86. 
PcG protein-mediated repression of transcription can be antagonized by TrxG proteins, 
which mediate the deposition of the H3K4me3 histone mark. TrxG proteins are a large 
family of transcriptional regulators that can be classified in three different categories: 1) 
SET-domain-containing proteins that trimethylate histone tails, 2) ATP-dependent 
chromatin-remodelling factors and 3) specific DNA-binding proteins and other TrxG 
proteins that are not included in the first two categories  101. Mammalian cells contain six 
non-redundant COMPASS-like complexes that are able to trimethylate lysine 4 on histone 
H3. COMPASS-like complexes are further classified depending on their subunit 
composition: Set1A- and Set1B-containing complexes mediate the bulk of H3K4me3 
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methylation in mammalian cells; Mixed Lineage Leukemia 1 (Mll1)-containing complexes 
deposit H3K4me3 on a smaller subset of genes, including Hox genes; Mll3- and Mll4-
containing complexes are involved in the activation of retinoic acid target genes. To 
conclude, even if we still miss the big picture, there is an increasing amount of data 
suggesting that the balance between PcG and TrxG proteins at a particular genomic locus 
is what determines the activation state of the target genes and is influenced by many 
different factor such as nucleosome positioning, the presence of activating or repressing 
histone marks, transcription of lncRNAs, the binding with basal transcription machinery 
and transcription factors  101, 102. 
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MATERIALS AND METHODS 
 
Cell culture 
 
The cell lines used in this study were: 
• ECs derived from murine embryonic stem cells with homozygous null mutation of 
the VE-cadherin gene (VEC-null)  103. The wild-type form of VE-cadherin was 
introduced in these cells (VEC-positive) using retrovirus-mediated transfer as 
described in detail by Lampugnani et al.  22; 
• Δβcat cells, ECs expressing a truncated mutant of VE-cadherin (lacking residues 
703-784 of human VE-cadherin)  104, which correspond to the β-catenin-binding 
region  22; 
• IL2-VEC cells, ECs expressing a mutated version of VE-cadherin made up of the 
VE-cadherin cytoplasmic domain (aminoacids 621-784) fused to the extracellular 
and transmembrane domains of IL-2 receptor α-chain (from Andrew Kowalczyk, 
Emory University, Atlanta, GA)  105, 106;  
• Δp120 cells, ECs expressing a truncated mutant of VE-cadherin (lacking residues 
621–702 of human VE-cadherin), which corresponds to the p120-binding region  
105, 107 
• β-catenin WT and β-catenin KO ECs were derived from lungs of adult β-
cateninflox/flox mice and immortalized with as previously described  103 and infected 
with an adenovirus encoding GFP (control) or CRE recombinase to obtain β-
catenin gene recombination (Monica Corada, unpublished data). 
 
For all ECs of murine origin, culture medium was DMEM (GIBCO) with 20%  North 
American (NA) fetal bovine serum (FBS) (HyClone), glutamine (2 mM; Sigma), 
penicillin/streptomycin (100 units/l; Sigma), sodium pyruvate (1 mM; Sigma), heparin 
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(100 µg/ml, from porcine intestinal mucosa; Sigma), and EC growth supplement (ECGS) 
(5 µg/ml, made in our lab from calf brain) (complete culture medium). 
Starving medium was MCDB 131 (GIBCO) with 1% bovine serum albumin (BSA) 
(EuroClone), glutamine (2 mM), penicillin/streptomycin (100 units/l) and sodium pyruvate 
(1mM). 
293T-Phoenix-Ecotropic packaging cells were provided by IFOM Cell Culture facility and 
cultured in DMEM medium supplemented with 10 % South American (SA) FBS 
(Hyclone), glutamine (2 mM) and sodium pyruvate (1 mM). 
Low passage AD-HEK293 cell line (human embryonic kidney, American Type Culture 
Collection, Manassas, VA), used for adenoviral production, were provided by IFOM Cell 
Culture facility and grown in DMEM medium supplemented with 10% FBS NA, 
glutamine (4 mM), penicillin/streptomycin (100 units/l), and sodium pyruvate (1 mM).  
All cells were cultured at 37°C in a humidified atmosphere with 5% CO2. 
 
 
Lentiviral and adenoviral preparations 
 
The following lentiviral constructs were used: 
• ΔN-βcatenin: encoding a stabilized mutant of β-catenin was obtained from C. 
Brancolini, University of Udine, Udine, Italy. 
• lentiviruses used to express a stable short hairpin RNA against Suz12 (shSuz12), 
for the overexpression of Suz12 and the respective control vectors were a kind gift 
of Diego Pasini, IEO, Milan. 
Packaging plasmids were kindly donated by L. Naldini (HSR-TIGET, San Raffaele 
Telethon Institute for Gene Therapy, Milan, Italy). Lentiviral vectors were produced as 
described by Dull et al.  108. Briefly, on day 1 293T-Phoenix-Ecotropic packaging cells 
were transfected with the viral genome using calcium phosphate and incubated overnight 
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with the transfection mix. On day 2 the medium containing the transfection mix was 
removed and 293T-Phoenix-Ecotropic cells were grown in as little medium as possible to 
concentrate the virus. On day 3 the medium containing the virus was removed, passed 
through a 0,45 µm diameter filter, supplemented with Polybrene (8 ug/ml, from IFOM Cell 
Culture facility) and placed on cells to be infected. The same procedure was repeated on 
day 4. shSuz12- and shEmpty-infected cells were selected with hygromycin 300 ug/ml. 
Cells were kept under selection until control non-infected cells died. Suz12-overexpressing 
cells and their Empty control were selected with Puromycin 3 ug/ml. Cells were kept under 
selection until control non-infected cells died. 
The FKHR-TM adenovirus has been previously described  52. The TCF4-DN adenovirus 
was kindly donated by S. J. George (Bristol Heart Institute, Bristol, UK)  109. Infectious 
viruses were purified and titered using standard techniques. Briefly, for adenovirus 
production AD-293T cells were infected with 2 pfu/cell in DMEM without serum for 1 h at 
37°C. Then, the infection medium was removed and cells were grown in an appropriate 
volume of DMEM + 5% horse serum until complete cell lysis is obtained (usually 72h 
later). The medium containing the viruses was then subjected to 3 freeze-and-thaw cycles 
in order to destroy all the cells and to set as many virions as possible free. The resulting 
supernatant was then centrifuged at 3000 rpm for 30 min at +4°C to eliminate the cellular 
debris, aliquoted and stored at -80°C. For the infection of ECs two consecutive cycles of 
infection [5 h and overnight (O/N)] were performed with MOI of 300 in 1 ml of complete 
culture medium. 
 
 
Immunofluorescence microscopy  
 
Immunofluorescence microscopy staining was performed using standard technique, as 
previously described  107. Briefly, cells were seeded on 0,5% cross-linked gelatin. Cells 
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were fixed and permeabilized in methanol at -20°C for 5 min. Fixed cells were incubated 
for 30 min in a blocking solution (PBS, phosphate buffer saline, containing Ca2+ and Mg2+, 
+/+, 2.5% skim-milk, 0.3% TritonX-100). Cells were then incubated for 1 h at RT with 
primary antibodies diluted in blocking buffer. Appropriate secondary antibodies were 
applied on cells for 45 min at RT and mounted with VECTASHIELD with DAPI (Vector 
Biolabs). 
Samples were observed under an epifluorescence microscope (DMR; Leica) using a 63X 
objective. Images were captured using a charge-coupled camera and processed with Adobe 
Photoshop. Only adjustments of brightness and contrast were used in the preparation of the 
figures. For comparison purposes, different sample images of the same antigen were 
acquired under constant acquisition settings.  
 
 
Western blot analysis 
 
Total proteins were extracted by solubilising cells in boiling Laemmli buffer [2.5% SDS 
and 0.125 M Tris-HCl (pH 6.8)]. Lysates were incubated for 5 min at 100°C to allow 
protein denaturation and then spinned for 5 min at 13200 rpm to discard cell debris. The 
supernatants were collected and the concentration of protein was determined using a 
BCA™ Protein Assay Kit (Pierce) according to manufacturer’s instructions. Equal 
amounts of proteins were loaded on gel and separated by SDS-PAGE, transferred to a 
Protran Nitrocellulose Hybridization Transfer Membrane 0.2 µm pore size (Whatman) and 
blocked for 1 h at RT in 1X Tris Buffered Saline Tween (TBST) [150 mM NaCl, 10 mM 
Tris-HCl (pH 7.4), and 0.05% Tween] containing 5% (w/v) powdered milk. The 
membranes were incubated overnight at 4°C or 1 h at RT with primary antibodies diluted 
in 1X TBST-5% BSA. Next, membranes were rinsed 3 times with 1X TBST for 5 min 
each and incubated for 1 h at RT with HRP-linked secondary antibodies (diluted in 1X 
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TBST-5% BSA). Membranes were rinsed 3 times with TBST for 5 min each and specific 
binding was detected by the enhanced chemiluminescence (ECL) system (Amersham 
Biosciences) using HyperfilmTM (Amersham Biosciences) or the ChemiDoc gel imaging 
system (BIORAD). The molecular masses of proteins were estimated relatively to the 
electrophoretic mobility of co-transferred prestained protein marker, Broad Range (Cell 
Signalling Technology). 
 
 
Co-immunoprecipitation  
 
Cells were grown until confluent and starved overnight. Cells were then washed once with 
DMEM without serum and incubated with 0,4 mg/ml of dithiobis(succinimidyl)propionate 
(DSP) (Pierce) for 30 min at 37°C. After several washes with ice-cold PBS, cells were 
lysed in ice-cold modified RadioImmunoPrecipitation Assay (RIPA) buffer (Tris HCl pH 
7.5 100 mM, NaCl 150 mM, Deoxycholic acid 1%, SDS 0,1%, CaCl2 2 mM). The protein 
lysate was precleared with an appropriate volume of Protein G Sepharose 4B (Zymed) for 
3 h at +4°C. Then, protein concentration was determined with BCA™ Protein Assay Kit 
and an equal amount of protein was incubated with either immune antibodies or species-
matched control antibodies overnight at +4°C. On the following day immunocomplexes 
were collected using Protein G Sepharose 4B for 3 h at +4°C. Beads were then washed 
several times with modified RIPA buffer and boiled in an appropriate volume of Laemmli 
buffer. Samples were analysed by standard Western blot analysis as described above  107. 
CoIP following biotinylation of membrane proteins was performed using the same protocol 
as above. Before cell lysis with modified RIPA buffer cells were incubated with Sulfo-
NHS-LC-Biotin (Pierce ThermoScientific) 0,55 mg/ml in PBS +/+ pH 8.0 for 30 min at 
+4°C. After biotinylation cells were washed with PBS +/+ pH 8.0 + Glycine 100 mM to 
quench the reaction. 
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CoIP from lung tissue: lungs from adult age-matched mice were lysed in ice-cold modified 
JS buffer (Hepes pH 7.5 72 mM, NaCl 210 mM, glycerol 0,5 %, Triton X-100 1%, MgCl2 
2 mM, EGTA 7.2 mM, SDS 0,1 %, Sodium Orthovanadate 300 µM, Pefabloc SC 1 mM 
[Sigma] and Sodium Fluoride 1 mM) using Tissue Lyser II (Quiagen) (two 30-sec pulses 
at maximum frequency). Samples were precleared for 4 h at +4°C with an appropriate 
volume of Protein G Sepharose 4B. Then, protein concentration was determined with 
BCA™ Protein Assay Kit and an equal amount of protein was incubated with Protein G 
Sepharose 4B pre-coupled with either immune antibodies or species-matched control 
antibodies overnight at +4°C. The day after, beads were then washed with modified JS 
buffer and boiled in an appropriate volume of Laemmli buffer. Samples were analysed by 
standard Western blot analysis  107. All the buffers contained freshly added protease 
inhibitor cocktail (IFOM Kitchen Facility). 
 
 
Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) analysis 
 
Total RNA was isolated by RNeasy kit (QIAGEN) and 1 µg was reverse transcribed with 
random hexamers (High Capacity cDNA Archive Kit, Applied Biosystems) according to 
the manufacturer’s instructions. cDNA (5 ng) was amplified in triplicate in a reaction 
volume of 15 µl using TaqMan Gene Expression Assay (Applied Biosystems) and an 
ABI/Prism 7900 HT thermocycler, using a pre-PCR step of 10 min at 95°C, followed by 
40 cycles of 15 sec at 95°C and 60 sec at 60°C. Preparations of RNA template without 
reverse transcriptase were used as negative controls. For any sample the expression level, 
normalized to the housekeeping gene 18S, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) or β2-microglobulin, was determined using the comparative threshold cycle 
(CT) method as previously described  110. 
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Transcription factor binding site analysis  
 
In order to identify FoxO1 and Tcf/β-catenin consensus sequences on the putative claudin-
5, VE-PTP and vWf promoter region we used the program MatInspector  111, which 
identifies transcription factor binding sites (TFBS) in nucleotide sequences using a large 
library of weight matrices. We analyzed the sequence spanning from 6000 bp upstream 
and 500 bp downstream the coding sequence (CDS) of the genes and obtained a prediction 
of a potential combination of TFBS. The TFBS sequences considered in the analysis were 
[AG][GA][TG][AC]AACAA[AC] for FoxO1 binding and 
[TAG][GT][AG][CT][AT]x(2)CAAAG[GCT][GAC][AC][GCA] for Tcf/β-catenin 
binding. Apart from VE-PTP promoter which has not been characterized yet, claudin-5 and 
vWf promoters have been at least in part investigated in previous works 112-114 . Burek et al. 
studied the 1000 bp residing 5' to murine claudin-5 transcription start site (TSS) and found 
six glucocorticoid-response elements (GREs), two NFkB sites, three Sp1, one Sp2, one 
Ap2 and three E-boxes 114. Taddei et al. investigated a larger portion of the regulatory 
regions flanking murine claudin-5 gene spanning from 6000 bp upstream to 500 bp 
downstream and found three clusters of predicted binding sites for FoxO1 and β-catenin. 
Among these regions, the one located most at 5' was found to be bound by both FoxO1 and 
β-catenin, while the 3' most region was bound only by β-catenin  26. In another report, 
human CLDN5 gene was found to contain a SOX-18 between -183 and -167 bp and four 
ETS consensus sites between -165 and -74 bp relative to the TSS of the gene. The authors 
show the importance of Sox18 for the proper expression of claudin-5 in confluent ECs 112. 
Since its cloning in 1987  115, vWf promoter has been extensively studied and, like in the 
case of claudin-5, many different TFs seem to participate to drive proper vWf expression 
in the vasculature. Murine vWf promoter contains a conserved GATA-binding site at -80 
bp and an ETS-binding site at -60 bp relative to its TSS  116. Interestingly, while the 110 bp 
downstream the TSS of murine vWf promoter have enhancing activity when cloned 
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upstream of Luciferase reporter gene, the regions that are located 5' to vWf  TSS have 
repressive activity 116. 
 
Chromatin immunoprecipitation  
 
Chromatin immunoprecipitation (ChIP) assays were carried out as previously described  
117. Briefly, cells were starved overnight and cross-linked with 1% PFA for 10 min at RT. 
PFA was then inactivated by the addition of 125 mM glycine for 5 min at RT. Cells were 
then washed twice with ice-cold PBS and resuspended in ice-cold SDS buffer (NaCl 100 
mM, Tris HCl pH 8,1 50 mM, EDTA 5mM, NaN3 0,2%, SDS 0,5%). The lysate was then 
centrifuged at 1300 rpm for 5 min at +4°C and the pellet was resuspended in IP buffer (1 
vol of SDS Buffer + 0,5 vol of Triton Dilution Buffer [NaCl 100 mM, Tris HCl pH 8,6 100 
mM, EDTA 5 mM, NaN3 0,2%, Triton X-100 5%]). Samples were sonicated with a 
BIORUPTORTM  200 using the following conditions: H power, 30 sec ON-60 sec OFF for 
20 min. To check the size of the sonicated chromatin, an aliquot is taken and digested with 
Proteinase K 1 ug/ul for 30 min at 55°C and incubated at 65°C for 3h to revert the cross-
linking. The samples are then purified using the QIAquick Gel extraction Kit (QIAGEN)  
and loaded on 1% agarose gel (Figure 9). 
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Figure 9 An aliquot of fragmented chromatin from ECs run on a 1% agarose gel  
 
 
Chromatin extracts containing from 200 µg to 1000 µg of DNA with an average size of 
500 bp were incubated overnight at +4°C with 5 µg of either immune antibody or matched 
non-immune antibodies and Dynabeads protein G (Invitrogen) or Ultralink resin protein 
A/G (Pierce ThermoScientific). On the following day, beads were recovered and washed 
twice with Mixed Micelle Wash Buffer (NaCl 150 mM, TrisHCl pH 8.1 20 mM, EDTA 5 
mM, Sucrose 5,2 % w/v, NaN3 0,02%, Triton X-100 1%, 0,2 % SDS), 500 Buffer 
(Deoxycholic acid 0,1% w/v, NaCl 500 mM, HEPES pH 7.5 25 mM, EDTA 1 mM, NaN3 
0,02%, Triton X-100 1%), LiCl Detergent wash Buffer (Deoxycholic acid 0,5% w/v, LiCl 
250 mM, EDTA 1 mM, NP-40 0,5% v/v, NaN3 0,02%, Tris HCl pH 8.0 10 mM). 
Proteins/DNA complexes were detached from beads by heating the samples at 65°C for 10 
min. De-crosslinking was performed at 65°C overnight. DNA was purified using 
phenol/chloroform and precipitated in 70% ethanol according to standard protocol. DNA 
was amplified by qRT-PCR techniques using oligonucleotides flanking the assayed 
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promoter regions. Every couple of primers was tested in advance to avoid "auto-
amplification" due to self-complementarity. 
For qRT-PCR analyses DNA was diluted in the presence of specific primers (0.4 µM each) 
to a final volume of 25 µl in SYBR Green Reaction Mix (Perkin Elmer). 
qRT-PCR curves were converted in Ct values using S.D.S 2.2.1 and further analyzed as 
follows. For each region the mean of the Cts of the inputs was calculated and subtracted to 
the Ct values of the immune samples (ΔCt). Then, the % of enrichment of input for the 
immune samples was obtained as 2^-ΔCt and multiplied by the % of input taken during the 
experiment. The same was performed for the non-immune (IgG control) samples and the 
non-immune values were subtracted from the immune samples to eliminate unspecific 
signal. In order to pool together ChIP experiments to perform statistical analysis, each 
technical replicate of at least 2 biological replicates was normalized to the average of the 
replicates of the respective reference condition (usually VEC-null cells). In this way the 
reference condition was set to 1 and the other experimental conditions were represented as 
fold change of the signal of the reference condition. Means were compared by Student's t-
test and significance was set at 0.05. 
 
   List of primers used for ChIP experiments 
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RNA interference  
 
Stealth RNAi Duplexes (Life Technologies) and the correspondent Low GC Stealth RNAi 
Control Duplexes (Life Technologies) were used to knockdown FoxO1. The sequences of 
the two siRNAs used were the following: 5'-CCAAGUGACUUGGAUGGCAUGUUUA-
3' and 5'-CAGACACUUCAGGACAGCAAAUCAA-3'. Transfection was performed using 
LipofectAMINE 2000 (Invitrogen) according to the manufacturer's instructions.  
 
 
Immunohistochemistry (IHC) 
 
Paraffin-embedded human ovarian tissue samples were kindly provided by Ugo Cavallaro 
(European Instiute of Oncology, IEO, Milan) and scored as pathologic or non-pathologic 
by a trained pathologist. Samples were de-paraffinized and hydrated as follows: 
Histolemon (Carlo Erba) 3 min, Ethanol (EtOH) 100% 3 min, EtOH 95% 3 min, EtOH 
80% 3 min, H2O 5 min. Samples underwent antigen unmasking in Sodium Citrate Buffer 
pH 6 for 45 min at 95°C and allowed to recover for 30 min at room temperature. 
Endogenous peroxydase activity was inhibited with H2O2 3% for 10 min and then washed 
with PBS. Slices were blocked in Preincubation Buffer (PBS containing FBS 1% and BSA 
0,6%) for 90 min at room temperature. Samples were incubated with primary antibodies 
diluted in Preincubation Buffer overnight at +4°C. Then, samples were washed several 
times with PBS and incubated for 20 min with MATCH 2 Double Stain 2 Kit (Biocare) 
containing anti-mouse HRP-conjugated and anti-rabbit alkaline phosphatase-conjugated 
secondary antibodies. Incubation with Vulcan Red and DAB were done subsequently for 
15 and 5 min, respectively. After several washes with H2O, haematoxylin/eosin staining 
was performed according to standard protocol and samples were mounted in Eukitt (Bio-
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Optica). Samples were then imaged under a transmission light microscope at the indicated 
magnification. 
 
 
 
Antibodies and chemicals  
 
Antibodies used in this study were: anti-claudin-5 mouse monoclonal clone 4C3C2, anti-
V5 tag mouse monoclonal R960-25 (Life Technologies); anti-claudin-5 rabbit polyclonal 
ab-53765, anti-total histone H3 ab1791 and anti-H3K4me3 RNA pol II phospho ser 5 
ab8580 (ABCAM); anti-β-catenin mouse monoclonal 610154, anti-Ezh2 mouse 
monoclonal 612666, anti-N-cadherin mouse monoclonal 610921, anti-pRB mouse 
monoclonal 554136, anti-p120 mouse monoclonal 610133 (BD Biosciences); anti-β-
catenin rabbit polyclonal 06-734, anti-Ezh2 rabbit polyclonal 07-689, anti-H3K27me3 07-
449, anti-TCF4 mouse monoclonal clone 6H5-3 05-511 (Millipore); anti-FKHR (H-130X) 
rabbit polyclonal sc-67140, anti-VE-cadherin goat polyclonal sc-6458, anti-vWf clone H-
300 rabbit polyclonal sc-14014, anti-Suz12 goat polyclonal sc-46264 (Santa Cruz 
Biotechnology); anti-vWf rabbit polyclonal AB7356 (Chemicon); anti-Hif1α rabbit 
polyclonal A300-286A (Bethyl Laboratories); anti-FoxO1 rabbit monoclonal clone C29H4 
2880, anti-phospho-FoxO1 (Ser 256) rabbit polyclonal 9461, anti-phospho-FoxO1 (Thr 24) 
rabbit polyclonal 9464, anti-Akt rabbit polyclonal 9272, anti-phospho-Akt (Thr 308) rabbit 
polyclonal 9275; anti-Myc-tag rabbit polyclonal 2272, anti-Suz12 rabbit monoclonal 
D39F6, anti-H3K27me3 clone C36B11 rabbit monoclonal BK9733BFS (Cell Signalling), 
peroxidase-conjugated streptavidin (Jackson ImmunoResearch Laboratories), anti-HA-tag 
mouse monoclonal clone 12CA5, anti-Bmi1 mouse monoclonal clone AF27 (from Kristian 
Helin), anti-Ezh2 clone AC22 and AE25-13, anti-α-tubulin mouse monoclonal, anti-
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vinculin mouse monoclonal (from internal service); anti-human VE-cadherin mouse 
monoclonal (BV9)  118, anti-VE-PTP Rabbit polyclonal (produced in our laboratory). 
The following reagents were used in this study: pan-caspase inhibitor Z-VAD-FMK 
(Promega); PI(3)K inhibitor LY 294002 (Cell Signalling Technology). To inhibit AKT 
activity, cells were starved for 24h in starving medium + 1% BSA and then treated 
overnight with LY 294002 20 µM or Dimethyl sufoxide (DMSO) 20 µM as a control. To 
avoid apoptotic cell death during FKHR-TM overexpression experiments, 24h after the 
beginning of the infection, cells were treated with Z-VAD-FMK 50 µM for 24h and with 
Z-VAD-FMK 100 µM for the next 24h hours.  
 
 
Statistical analysis  
 
Student’s two-tailed unpaired t-test was used to determine statistical significance. The 
significance level was set at P < 0.05. 
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RESULTS 
 
VE-cadherin clustering triggers an endothelial stabilisation transcriptional 
programme 
 
Previous work demonstrated that VE-cadherin expression and clustering at AJs is 
necessary for claudin-5 upregulation  26 (see also Figure 10). In order to investigate 
whether VE-cadherin was able to regulate in the same fashion other genes related to 
vascular stabilisation, we exploited previously generated Affymetrix data  26, comparing a 
mouse VE-cadherin-null cell line (VEC-null) with the same line reconstituted with VE-
cadherin wild type cDNA (VEC-positive), described previously  22. We identified two 
other genes that are preferentially expressed in the endothelium and that are fundamental 
for vessel stabilisation: VE-PTP and vWf  26. As confirmed by quantitative real-time PCR 
(qRT-PCR), both genes were strongly upregulated by VE-cadherin expression (compare 
confluent VEC-null with VEC-positive) and cell confluence (compare VEC-positive in 
sparse and confluent conditions) (Figure 11a and 12a). Data were confirmed by western 
blot (WB) and immunofluorescence (IF) (Figure 11b and c and 12b and c). 
   
Figure 10 Claudin-5 expression in confluent VEC-null and VEC-positive ECs  
IF microscopy analysis of claudin-5 expression and confluent VEC-null and VEC-positive ECs. Cells were 
double stained with anti-claudin-5 (red) and anti-VE-cadherin (green) antibodies. Scale bar = 10 µm. 
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Figure 11 VE-cadherin clustering upregulates the endothelial-stabilisation gene VE-PTP  
(a) qRT-PCR analysis of VE-PTP expression in sparse (sp) and confluent (con) VEC-null and VEC-positive 
ECs. The levels of mRNA are normalized to 18S; columns are means ± s.e.m. of triplicates from a 
representative experiment (n=3). (b) WB analysis of VE-PTP in extracts of confluent VEC-null and VEC-
positive ECs. Vinculin was used as a loading control. (c) IF microscopy analysis of VE-PTP expression and 
confluent VEC-null and VEC-positive ECs. Cells were double stained with anti-VE-PTP (red) and anti-VE-
cadherin (green) antibodies. Scale bar = 10 µm.  
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Figure 12 VE-cadherin clustering upregulates the endothelial-stabilisation gene vWf  
(a) qRT-PCR analysis of vWf expression in sparse (sp) and confluent (con) VEC-null and VEC-positive ECs. 
The levels of mRNA are normalized to 18S; columns are means ± s.e.m. of triplicates from a representative 
experiment (n=3). (b) WB analysis of vWf in extracts of confluent VEC-null and VEC-positive ECs. 
Vinculin was used as a loading control. (c) IF microscopy analysis of vWf expression and confluent VEC-
null and VEC-positive ECs. Cells were double stained with anti-vWf (red) and anti-VE-cadherin (green) 
antibodies. Scale bar = 10 µm.  
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Other evidence in the literature point to a confluence-dependent expression of VE-PTP 
and vWf in primary and immortalized ECs. Nottebaum et al., for instance have shown that 
VE-PTP expression is increased in long-confluent mouse bEnd.3 endothelioma cell line 
compared to the subconfluent counterpart 76. Similarly, Howell et al. showed that vWf 
accumulates inside Weibel-Palade bodies in HUVECs primary ECs as cells reach 
confluency 127. 
 To demonstrate how VE-cadherin clustering was essential for VE-PTP and vWf 
upregulation we expressed in VEC-null cells a mutant version of VE-cadherin composed 
of the cadherin cytoplasmic tail fused to the transmembrane and extracellular domains of 
interleukin-2 receptor α-chain (IL2-VEC). This mutant is unable to cluster at cell-cell 
contacts, although it retains the capacity to associate with VE-cadherin intracellular 
partners  105, 106. Neither of the two analysed genes was upregulated upon IL2-VEC 
expression in confluent endothelial cells, confirming the need for VE-cadherin clustering 
for their full expression (Figure 13a and b). These data extend what previously 
demonstrated for claudin-5  26, indicating that VE-cadherin clustering at AJs is required for 
the expression of a set of vascular stability genes. 
 
 
Figure 13 VE-cadherin clustering is required for VE-PTP and vWf expression 
qRT-PCR analysis of VE-PTP (a) and vWf  (b) expression in confluent VEC-null, VEC-positive and IL2-
VEC ECs. The levels of mRNA are normalized to 18S; columns are means ± s.e.m. of replicates of a 
representative experiment (n=3). t-test: *P < 0.01 
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FoxO1 and β-catenin repress VE-PTP and vWf expression 
 
FoxO1 and β-catenin have previously been shown to associate with each other and bind 
claudin-5 promoter to induce gene repression. This is counteracted by VE-cadherin 
clustering, which reduces FoxO1 and β-catenin nuclear levels  26. We aimed at verifying if 
this same mechanism was involved in VE-cadherin-mediated induction of VE-PTP and 
vWf expression. We infected confluent VEC-positive cells with adenoviruses encoding 
control green fluorescent protein (GFP) or a constitutively active form of FoxO1 (FKHR-
TM, triple mutant) which contains mutations of all three AKT-target phosphorylation sites 
(Thr 24, Ser 256 and Ser 319) and therefore can not be inhibited  52. FKHR-TM expression 
led to a strong downregulation of both VE-PTP and vWf expression (Figure 14a and b).  
 
    
 
 
Figure 14 Analysis of VE-PTP and vWf expression upon FKHR-TM overexpression 
qRT-PCR analysis of VE-PTP (a) and vWf (b) expression in VEC-null and VEC-positive ECs either 
uninfected or infected with adenoviral vectors encoding FKHR-TM or GFP as a negative control. 24h after 
the infection cells were cultured in the presence of the pan-caspase inhibitor Z-VAD-FMK to limit the 
proapoptotic effect of FKHR-TM (see more details in Materials and Methods). The levels of mRNA are 
normalized to GAPDH, columns are means ± s.e.m. of triplicates from a representative experiment (n=3). t-
test: *P < 0.01. 
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Results were confirmed by increasing endogenous FoxO1 activity via LY 294002-
mediated inhibition of PI3K. Treatment reduced FoxO1 Ser 256 phosphorylation level 
(Figure 15c) and yielded the downregulation of both analysed genes (Figure 15a and b).  
 
 
 
         
Figure 15 Analysis of VE-PTP and vWf expression upon pharmacological inhibition of PI3K/AKT 
pathway 
qRT-PCR analysis of VE-PTP (a) vWf (b) expression in confluent VEC-null and VEC-positive ECs treated 
with the PI(3)K inhibitor LY294002 or DMSO as control.  (c) WB analysis of of p-FoxO1 Ser 256 and total 
FoxO1 protein. Vinculin was used as loading control. The levels of mRNA are normalized to GAPDH, 
columns are means ± s.e.m. of triplicates from a representative experiment (n=3). t-test: *P < 0.01. 
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β-Catenin is known to associate with FoxO1 increasing its repressor activity on claudin-5 
by stabilizing its binding to gene promoters  26. Interestingly, the expression of a stabilised 
version of β-catenin lacking the GSK3β phosphorylation site (ΔN-β-catenin), led to a 
marked downregulation of both VE-PTP and vWf genes, suggesting a similar mechanism to 
claudin-5 regulation (Figure 16a and b).  
        
Figure 16 Analysis of VE-PTP and vWf expression upon ΔN-β-catenin overexpression 
qRT-PCR analysis of VE-PTP (a) and vWf (b) expression in confluent VEC-null and VEC-positive cells 
expressing ΔN-β-catenin or GFP as negative control. The levels of mRNA are normalized to GAPDH, 
columns are means ± s.e.m. of triplicates from a representative experiment (n=3). t-test: *P < 0.01.  
 
 
We performed a promoter analysis spanning from 6000 base pairs (bp) upstream to 500 bp 
downstream of the transcription start site (TSS) of VE-PTP and vWf genes and identified a 
series of paired Tcf/β-catenin-FoxO1 binding sites localized in three different regions on 
both promoters: Region 1 (position -5,257/-5,158 for VE-PTP; -3,836/-3,354 for vWf); 
Region 2 (position -3,206/-2,656 for VE-PTP; -733/-556 for vWf); Region 3 (position -
1,697/-1,263 for VE-PTP; -49/+83 for vWf) (Figure 17a and b).  
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Figure 17 Schematic representation of the putative promoter regions of VE-PTP and vWf 
Tcf/β-catenin and FoxO binding sites identified on the putative promoter region of  VE-PTP (a) and vWf  (b) 
gene. FoxO1 (F) binding sites are depicted as white boxes and Tcf/β catenin (T) binding sites as black boxes. 
CDS, coding sequence. Primers are depicted as black arrows. TSS, transcription start site. Promoter analysis 
was performed using MatInspector software (see Materials and Methods). 
 
Quantitative chromatin immunoprecipitation (qChIP) showed that FoxO1 binds all three 
regions in both promoters (Figure 18a and b). Binding occurred only in confluent VEC-
null and not in confluent VEC-positive cells, correlating with gene repression. 
Furthermore, β-catenin also bound all identified regions with different affinity (Figure 19a 
and b). Overall, these data show that VE-cadherin clustering at AJs triggers a vascular 
stabilisation transcriptional programme, consisting at least in the expression of claudin-5, 
VE-PTP and vWf through the inhibition of the repressive activity exerted by FoxO1/β-
catenin-binding to their promoters. 
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Figure 18 FoxO1 binds to VE-PTP and vWf promoter regions 
qRT-PCR for Region 1, 2 and 3 of VE-PTP (a) and vWf (b) putative promoter regions performed on 
endogenous FoxO1-bound chromatin immunoprecipitated from confluent VEC-null and VEC-positive ECs. 
Columns are means ± s.d. of the fold enrichment normalized on the signal of VEC-null cells (n=3). t-test: *P 
< 0.01. 
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Figure 19 β-catenin binds to VE-PTP and vWf promoter regions 
qRT-PCR for Region 1, 2 and 3 of VE-PTP (a) and vWf (b) putative promoter regions performed on 
endogenous β-catenin-bound chromatin immunoprecipitated from confluent VEC-null and VEC-positive 
ECs. Columns are means ± s.d. of the fold enrichment normalized on the signal of VEC-null cells (n=3). t-
test: *P < 0.01.   
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Claudin-5, VE-PTP and vWf are Polycomb-target genes 
 
The mechanism through which FoxO factors can downregulate several target genes is still 
a matter of investigation. We aimed at clarifying how the FoxO1/β-catenin complex might 
act on claudin-5, VE-PTP and vWf genes to induce their repression. The observed 
regulation consists of a reversible inhibition of gene expression, depending on the state of 
cell confluence and AJ organization. Given the endothelial-specificity of the identified 
genes we hypothesized the possible involvement of PcG proteins, a group of 
transcriptional regulators involved in cell specification, which mediate reversible inhibition 
of transcription  87. In order to investigate this possibility we performed qChIP for PcG 
proteins on the TSS of claudin-5, VE-PTP and vWf genes. Gene TSSs displayed higher 
enrichments in the components of both PRC2 (Ezh2 and Suz12) and PRC1 (Bmi1) in 
confluent VEC-null than in VEC-positive cells (Figure 20 b, c and d).  
 
 
Figure 20 PcG proteins bind the TSS of claudin-5, VE-PTP and vWf genes in VEC-null ECs 
qRT-PCR for the TSS of claudin-5, VE-PTP and vWf performed on endogenous H3K27me3- (a), Suz12- (b), 
Ezh2- (c) and Bmi1- (d) bound chromatin immunoprecipitated from confluent VEC-null and VEC-positive 
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ECs. Columns are means ± s.d. of the fold enrichment normalized on the signal of VEC-null cells (n=3). t-
test: *P < 0.01. 
 
The mark of Ezh2 enzymatic activity, H3K27me3, also showed a similar enrichment 
pattern (Figure 20a), and qChIP for total histone H3 showed comparable enrichments at 
the analysed regions in VEC-null and VEC-positive cells (Figure 21), ruling out the 
possibility that the higher H3K27me3 signal in VEC-null cells could be due to higher 
histone density.  
 
   
Figure 21 Histone density on the TSS of claudin-5, VE-PTP and vWf genes is not affected by the 
absence of VE-cadherin 
qRT-PCR for the TSS of claudin-5, VE-PTP and vWf performed on total H3-bound chromatin 
immunoprecipitated from confluent VEC-null and VEC-positive ECs. Columns are means ± s.d. of the fold 
enrichment normalized on the signal of VEC-null cells (n=3). t-test: ns, not significant. 
 
 
PcG protein-mediated repression is counteracted by the activity of Trithorax group (TrxG) 
proteins, which catalyse the deposition of H3K4me3 histone mark, leading to gene 
activation  101. As expected, claudin-5, VE-PTP and vWf TSSs showed a higher enrichment 
for H3K4me3 in confluent VEC-positive cells than in VEC-null (Figure 22a), consistently 
with gene activation in the presence of VE-cadherin clustering. In line with this 
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observation, RNA Pol II phosphorylated on Ser 5, a modification needed for the enzyme to 
escape the promoter and transcribe the gene   119, was present to a higher extent at the TSSs 
of genes in confluent VEC-positive cells (Figure 22b), where genes are actively 
transcribed. 
   
     
        
Figure 22 Activation marks decorate the TSS of claudin-5, VE-PTP and vWf genes in VEC-positive 
ECs 
qRT-PCR for the TSS of claudin-5, VE-PTP and vWf performed on endogenous H3K4me3- (a) and 
pRNAPolII Ser 5- (b) bound chromatin immunoprecipitated from confluent VEC-null and VEC-positive 
ECs. Columns are means ± s.d. of the fold enrichment normalized on the signal of VEC-null cells (n=3). t-
test: *P < 0.01. 
 
To further prove the role of PcG proteins in the transcriptional regulation of claudin-5, VE-
PTP and vWf genes we overexpressed the PRC2 member Suz12 in confluent VEC-positive 
cells using lentiviral-mediated gene delivery (Figure 23a). Even if PRC2 proteins are 
known to promote each other stability by physical interaction 120, 121, Suz12 overexpression 
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led only to a minor increase of Ezh2 protein levels that did not reach statistical significance 
(Figure 23b). Upon Suz12 overexpression in VEC-positive ECs claudin-5, VE-PTP and 
vWf expression was reduced (Figure 24a, b and c). As control, claudin-12 mRNA levels 
were unaffected by Suz12 overexpression in VEC-positive ECs (Figure 24 d).  
 
    
  
Figure 23 Suz12 overexpression in VEC-positive ECs  
(a) WB analysis of Suz12, Ezh2, FoxO1, β-catenin and H3K27me3 in extracts of confluent VEC-null and 
VEC-positive ECs infected with lentiviral vectors inducing Suz12 overexpression or Empty control. Tubulin 
was used as loading control. (b) WB quantification. For each protein, bands are normalized on tubulin and 
represented as percentage of the signal in VEC-null cells (n=3). t-test: *P<0.01; ns, not significant. 
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Figure 24 Suz12 overexpression represses claudin-5, VE-PTP and vWf expression 
qRT-PCR analysis of claudin-5 (a), VE-PTP (b) and vWf (c) in confluent VEC-null and VEC-positive ECs 
infected with lentiviral vectors inducing Suz12 overexpression or with an Empty control. Claudin-12 (d) 
levels are unchanged upon Suz12 overexpression. The levels of mRNA are normalized to 18S, columns are 
means ± s.e.m. of triplicates from a representative experiment (n=3). t-test: *P < 0.05; ** P<0.01; ns, not 
significant. 
 
 
Conversely, lentiviral delivery of short hairpin (sh)RNA was used to stably knockdown 
Suz12 in confluent VEC-null cells. As expected, Suz12 knockdown led to a marked 
decrease in Ezh2 and H3K27me3 levels, while β-catenin was unaltered (Figure 25a). Of 
note, FoxO1 protein level was about 30% lower upon Suz12 knockdown (Figure 25b), 
although FoxO1 mRNA expression was not influenced (Figure 26). This is suggestive of a 
possible effect of Suz12 on the regulation of FoxO1 protein stability.   
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Figure 25 Suz12 knockdown in VEC-null ECs 
(a) WB analysis of Suz12, Ezh2, FoxO1, β-catenin, H3K27me3 in extracts of confluent VEC-null ECs 
infected with lentiviral vectors inducing Suz12 knockdown (sh-Suz12) or Empty control (sh-Empty). (b) WB 
quantification. For each protein, bands are normalized on total histone H3 and represented as percentage of 
the signal in VEC-null sh-Empty cells (n=3). t-test: *P < 0.05; ** P<0.01; ns, not significant. 
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Figure 26 Analysis of FoxO1 expression upon stable Suz12 knockdown 
qRT-PCR analysis of FoxO1 expression in confluent VEC-null sh-Empty and VEC-null sh-Suz12 ECs. The 
levels of mRNA are normalized to 18S; columns are means ± s.e.m. of replicates of a representative 
experiment (n=3). t-test: ns, not significant. 
 
 
Suz12 knockdown abolished Suz12 signal at the TSS of claudin-5, VE-PTP and vWf genes 
(Figure 27) causing a partial reactivation of their expression (Figure 28). Together these 
data prove that the expression of the identified stabilisation genes is finely tuned at the 
epigenetic level by the balanced activity of PcG and TrxG proteins, which depends on the 
state of cell confluence and AJ organization. 
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Figure 27 Suz12 binding to the TSS of claudin-5, VE-PTP and vWf genes upon Suz12 stable 
knockdown 
qRT-PCR for the TSS of claudin-5, VE-PTP and vWf performed on endogenous Suz12-bound chromatin 
immunoprecipitated from confluent VEC-null, VEC-null-sh-Empty and VEC-null-sh-Suz12 ECs. Columns 
are means ± s.d. of the fold enrichment normalized on the signal of VEC-null sh-Empty cells (n=3). t-test: *P 
< 0.01. 
 
      
    
Figure 28 Analysis of claudin-5, VE-PTP and vWf expression upon stable Suz12 knockdown 
qRT-PCR analysis of claudin-5 (a), VE-PTP (b) and vWf (c) in confluent VEC-null-sh-Empty and VEC-null-
sh-Suz12 ECs. The levels of mRNA are normalized to 18S; columns are means ± s.e.m. of replicates of a 
representative experiment (n=3). t-test: *P < 0.05; ** P<0.01.  
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FoxO1/β-catenin complex recruits PcG proteins at claudin-5, VE-PTP and vWf 
promoters 
 
A key aspect of PcG protein biology which still remains largely unravelled deals with PcG 
protein recruitment to their target sites  87. Given the absence of defined mammalian PREs, 
PcG protein recruitment to chromatin has been suggested to occur through PRC-interaction 
with specific DNA-binding partners. For instance, Snail1 transcription factor has been 
proved to associate to PRC2 components and target them to E-cadherin promoter to induce 
gene repression  100. We hypothesized that the FoxO1/β-catenin complex could act as PcG 
protein-recruiter to the promoters of the identified genes. We checked by co-
immunoprecipitation the association of Ezh2 and Suz12 with overexpressed constitutively 
active FKHR-TM and found this transcription factor interacting with both PcG proteins 
(Figure 29). This association was confirmed also in basal conditions, between Ezh2, Suz12 
and endogenous FoxO1 (Figure 30). 
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Figure 29 FKHR-TM interacts with PcG proteins 
CoIP and WB analysis of either endogenous Ezh2 (a) or Suz12 (b) and FKHR-TM from extracts of confluent 
VEC-null and VEC-positive ECs expressing either FKHR-TM (myc tagged) or GFP as negative control. To 
limit the pro-apoptotic effect of FKHR-TM cells were cultured in the presence of the pan-caspase inhibitor 
Z-VAD-FMK (see more details in Materials and Methods). Cells were lysed 72h after infection. TL, total 
lysate. Negative control Abs used in these experiments were anti-HA tag mouse mAb in (a) and non-immune 
rabbit IgG in (b).  
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Figure 30 Endogenous FoxO1 interacts with PcG proteins 
CoIP and WB analysis of endogenous Ezh2 (a) or Suz12 (b) and FoxO1 from extracts of confluent VEC-null 
and VEC-positive ECs. Arrow indicates specific FoxO1 band. TL, total lysate. Negative control Abs used in 
these experiments were anti-HA tag mouse mAb in (a) and non-immune rabbit IgG in (b).  
 
 
Of note, such interaction seemed to occur also in the presence of VE-cadherin expression 
and clustering in confluent VEC-positive cells (Figure 30). However, given the negligible 
levels of FoxO1-DNA binding at the promoters of claudin-5  26, VE-PTP and vWf in such 
condition (Figure 18), this complex is unlikely to be recruited at target sites. FKHR-TM 
overexpression in VEC-positive confluent cells led to a marked increase of H3K27me3 
binding to the TSS of claudin-5, VE-PTP and vWf genes, as shown by H3K27me3 qChIP 
(Figure 31a). This is in line with the gene downregulation observed upon FKHR-TM 
overexpression (Figure 14 and see Taddei et al., 2008). Moreover, no increase in Ezh2 
protein levels was induced by FKHR-TM (Figure 31b), proving that the augmented 
H3K27me3 enrichment seen in qChIP was not caused by Ezh2 protein upregulation.  
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Figure 31 FKHR-TM overexpression increases H3K27me3 levels on the TSS of claudin-5, VE-PTP and 
vWf genes 
(a) qRT-PCR for the TSS of claudin-5, VE-PTP and vWf performed on endogenous H3K27me3-bound 
chromatin immunoprecipitated from confluent VEC-null and VEC-positive ECs expressing either FKHR-TM 
or GFP as negative control. Columns are means ± s.d. of the fold enrichment normalized on the signal of 
VEC-null cells (n=3). t-test: *P < 0.01.  (b) WB analysis of FKHR-TM and Ezh2 in extracts from confluent 
VEC-null and VEC-positive ECs expressing either FKHR-TM or GFP. Vinculin was used as loading control. 
 
 
 
Conversely, endogenous FoxO1 knockdown strongly reduced Ezh2 recruitment at target 
sites in VEC-null cells (Figure 32a), in the absence of any Ezh2 downregulation (Figure 
32b and c). 
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Figure 32 FoxO1 knockdown impairs Ezh2 binding to the TSS of claudin-5, VE-PTP and vWf genes 
(a) qRT-PCR for the TSS of claudin-5, VE-PTP and vWf performed on endogenous Ezh2-bound chromatin 
immunoprecipitated from confluent VEC-null ECs either transfected with a control siRNA or with 2 different 
siRNAs targeting FoxO1 and VEC-positive ECs. Columns are means ± s.d. of the fold enrichment 
normalized on the signal of VEC-null control siRNA cells (n=3).  
(b)WB analysis of FoxO1 and Ezh2 on confluent VEC-null ECs transfected either with a control siRNA or 
with 2 different siRNAs targeting FoxO1 and VEC-positive ECs. Vinculin was used as a loading control. 
(c) WB quantification. For each protein, bands are normalized on vinculin and represented as percentage of 
the signal in VEC-null control siRNA cells (n=3). t-test: *P < 0.05; ** P<0.01; ns, not significant. 
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Co-expression of Suz12 and FKHR-TM in VEC-positive confluent cells induced a 
significantly stronger repression of claudin-5 (75,3%) than expression of FKHR-TM alone 
(about 53,1%), further maintaining the hypothesis that FoxO1-mediated downregulation 
occurs through Polycomb activity (Figure 33).  
 
 
 
 
Figure 33 FKHR-TM and Suz12 cooperate in repressing claudin-5 gene 
(a) WB analysis of FKHR-TM, Suz12, H3K27me3 and Claudin-5 in extracts of confluent VEC-null, VEC-
positive-Empty and VEC-positive-Suz12 ECs expressing either FKHR-TM or GFP as negative control. 
Tubulin was used as loading control.  
(b) qRT-PCR analysis of claudin-5 in VEC-null, VEC-positive-Empty and VEC-positive-Suz12 ECs 
expressing either FKHR-TM or GFP as negative control. The levels of mRNA are normalized to GAPDH. 
Columns are means ± s.d. of triplicates from a representative experiment (n=3). t-test: * P<0.01.  
 
 
We investigated whether β-catenin was part of FoxO1/PcG protein complex. Co-
immunoprecipitation experiments showed an interaction of β-catenin with both Ezh2 
(Figure 34a) and Suz12 (Figure 34b). As observed for FoxO1 (see above), also this 
association was present both in confluent VEC-null and VEC-positive cells but the lack of 
β-catenin binding to claudin-5, VE-PTP and vWf promoters in confluent VEC-positive 
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cells (Figure 19 and see Taddei et al., 2008) ruled out a possible recruitment of the 
complex to the DNA in this latter condition. Surprisingly we detected a strong Ezh2/β-
catenin association in VEC-positive confluent cells that was unlikely to be connected to the 
analysed recruitment mechanism (Figure 34a). The meaning of this interaction will be 
further explored in the next section.  
 
              
                       
 
Figure 34 β-catenin interacts with PcG proteins 
CoIP and WB analysis of either endogenous Ezh2 (a) or Suz12 (b) and β-catenin from extracts of confluent 
VEC-null and VEC-positive ECs. TL, total lysate. Negative control Abs used in these experiments were anti-
HA tag mouse mAb in (a) and non-immune rabbit IgG in (b).  
 
 
β-Catenin/FoxO1 association is known to stabilise FoxO1 binding to claudin-5 promoter 
and β-catenin/DNA interaction occurs via Tcf 26. To test whether the observed β-
  87 
catenin/PcG protein association had a similar stabilizing effect on Polycomb binding to 
target sites we overexpressed in confluent VEC-null cells a dominant negative form of 
TCF4 (TCF4-DN)  109, containing the DNA-binding domain but lacking the β-catenin-
interacting region. TCF4-DN is able to abolish β-catenin/DNA interaction and weakens 
FoxO1 binding at claudin-5 promoter  26. The expression of such construct weakened Ezh2 
binding to claudin-5 and VE-PTP promoters (Figure 35), while vWf promoter shows only a 
trend of downregulation. These findings suggest a stabilizing role for β-catenin on PcG 
protein association to target sites.  
 
 
 
 
  
Figure 35 β-catenin stabilises Ezh2 to the the TSS of claudin-5, VE-PTP genes 
qRT-PCR for the TSS of claudin-5, VE-PTP and vWf performed on endogenous Ezh2-bound chromatin 
immunoprecipitated from confluent VEC-null ECs expressing either TCF4-DN or GFP (as a negative 
control) and VEC-positive ECs. Columns are means ± s.d. of the fold enrichment normalized on the signal of 
VEC-null GFP cells (n=3). t-test: *P < 0.05. Inset: WB analysis of TCF4-DN (V5 tag) and Ezh2 in extracts 
from confluent VEC-null ECs expressing either TCF4-DN or GFP and VEC-positive ECs. Vinculin was used 
as loading control. 
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VE-cadherin associates with Ezh2 and sequesters it at the plasma membrane 
 
The strong Ezh2/β-catenin association detected in confluent VEC-positive cells (Figure 
34a) prompted us to hypothesize an alternative role for their interaction in this cell type. 
Surprisingly, Ezh2 co-immunoprecipitated with endogenous full length VE-cadherin 
(Figure 36a) suggesting that Ezh2/β-catenin interaction in VEC-positive cells might occur 
preferentially at cadherin complexes. Conversely, no interaction was detected between 
Ezh2 and N-cadherin (Figure 36b), which is strongly upregulated in the absence of VE-
cadherin in confluent VEC-null cells  19. Ezh2/VE-cadherin interaction was confirmed both 
in vitro using another anti-Ezh2 antibody (Millipore) (Figure 37) and in vivo from adult 
mice-derived whole lung extracts (Figure 38). 
   
   
               
 
Figure 36 Ezh2 associates with VE-cadherin but not with N-cadherin in vitro 
CoIP and WB analysis of endogenous Ezh2 with either VE-cadherin (a) or N-cadherin (b) from extracts of 
confluent VEC-null and VEC-positive ECs. TL, total lysate. In both (a) and (b) anti-HA tag mouse mAb was 
used as negative control Ab. 
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Figure 37 Ezh2 association with VE-cadherin probed with a different antibody (Millipore) 
CoIP and WB analysis of endogenous Ezh2 with VE-cadherin from extracts of confluent VEC-null and 
VEC-positive ECs. TL, total lysate. Non-immune rabbit IgG were used as negative control. 
 
 
   
Figure 38 Ezh2 associates with VE-cadherin in vivo 
CoIP and WB analysis of Ezh2 and VE-cadherin from murine whole lung extracts. Anti-HA tag mouse mAb 
was used as negative control Ab. 
 
 
 
We also checked if VE-cadherin could interact also with other PcG proteins. Surprisingly, 
we could not see any VE-cadherin co-immunoprecipitated by anti-Suz12 Ab (Figure 39), 
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thus suggesting that VE-cadherin binds selectively Ezh2 protein and not other PcG 
proteins.  
 
 
   
   
 
 
Figure 39 Suz12 does not interact with VE-cadherin 
CoIP and WB analysis of endogenous Suz12 with VE-cadherin from extracts of confluent VEC-null and 
VEC-positive ECs. TL, total lysate. Non-immune rabbit IgG were used as negative control Ab. 
 
 
Cytoplasmic localization of Ezh2 has been previously described  122. Moreover, membrane 
sequestration of another PcG protein, Eed, via interaction with Nef or activated integrins is 
a known mechanism exploited by human immunodeficiency virus (HIV) to reduce nuclear 
PcG protein activity and promote Trans-Activator of Transcription (Tat)-/Negative 
Regulatory Factor (Nef)-mediated transcription of the viral genome  123. Biotinylation of 
cell surface proteins further proved that Ezh2 associates with biotinylated VE-cadherin 
exposed on the membrane (Figure 40), supporting the hypothesis that the observed 
cadherin-Ezh2 interaction sequesters the Polycomb protein at the cell membrane.  
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Figure 40 Ezh2 interacts with VE-cadherin at the plasma membrane 
CoIP and WB analysis of endogenous Ezh2 and VE-cadherin from extracts of confluent VEC-null and VEC-
positive ECs after biotinylation of membrane proteins. TL, total lysate. * marks the biotinylated band of VE-
cadherin specifically immunoprecipitated by Ezh2 in VEC-positive ECs. Anti-HA tag mouse mAb was used 
as negative control Ab.  
 
 
Within the framework of trying to characterise Ezh2/VE-cadherin interaction, we 
investigated a putative role for β-catenin. Ezh2-VE-cadherin association was strongly 
reduced in a β-catenin-knockout endothelial cell line derived from adult mouse lung (β-
catenin KO) (Monica Corada, unpublished data) compared to the wild-type counterpart (β-
catenin WT) (Figure 41).  
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Figure 41 β-catenin mediates Ezh2 binding to VE-cadherin 
CoIP and WB analysis of endogenous Ezh2 and VE-cadherin from extracts of confluent β-catenin KO and β-
catenin WT ECs. TL, total lysate. Anti-HA tag mouse mAb was used as negative control Ab.  
 
 
Furthermore, VEC-null cells were reconstituted with a truncated mutant of VE-cadherin 
lacking the β-catenin-binding domain (Δβcat)  22. This VE-cadherin mutant is unable to 
sequester β-catenin at the membrane and displayed a marked reduction of Ezh2 binding 
(Figure 42). Interestingly, β-catenin was not the only VE-cadherin partner regulating Ezh2 
association. The expression of another VE-cadherin mutant, lacking the p120-catenin 
binding site but still able to bind β-catenin (Δp120)  22 showed an even greater reduction of 
Ezh2 association (about 90% reduction in Δp120 and 60% reduction in Δβcat compared to 
wild-type VE-cadherin) (Figure 42a and b).                    
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Figure 42 Ezh2/VE-cadherin association is reduced in both Δβcat and Δp120 ECs 
(a) CoIP and WB analysis of Ezh2 and VE-cadherin from extracts of confluent VEC-positive, Δβcat and 
Δp120 ECs. TL, total lysate. Δβcat and Δp120 VE-cadherin mutants show a lower molecular weight 
compared to WT VE-cadherin due to the deletion in their cytoplasmic tail (see also Lampugnani et al., 2002). 
Anti-HA tag mouse mAb was used as negative control Ab.  
(b) Quantification of relative Ezh2/VE-cadherin association normalized to VEC-positive ECs (n=3). t-test: 
*P < 0.05; **P < 0.01.  
 
In line with this observation, Ezh2 co-immunoprecipitated with endogenous p120-catenin 
as well (Figure 43). Altogether, these results show that Ezh2 is recruited at cell-cell 
contacts by clustered VE-cadherin and such association depends on cadherin binding to β-
catenin and p120-catenin. 
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Figure 43 Ezh2 interacts with p120 catenin 
CoIP and WB analysis of endogenous Ezh2 with p120-catenin from extracts of confluent VEC-null and 
VEC-positive ECs. TL, total lysate. Anti-HA tag mouse mAb was used as negative control Ab.  
 
 
 
Accordingly, claudin-5, VE-PTP and vWf gene expression was strongly reduced in Δp120 
cells (Figure 44). These findings suggest that the inhibition of p120 binding to VE-
cadherin most likely reduces the amount of Ezh2 that is sequestered out of the nucleus by 
VE-cadherin, thus facilitating the repression claudin-5, VE-PTP and vWf.  
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Figure 44 Δp120 ECs fail to upregulate claudin-5, VE-PTP and vWf 
qRT-PCR analysis of claudin-5 (a), VE-PTP (b) and vWf (c) in confluent VEC-null, VEC-positive and 
Δp120 ECs. The levels of mRNA are normalized to 18S. Columns are means ± s.d. of triplicates from 
representative experiments (n=3). t-test: * P<0.01.  
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VE-cadherin regulates Ezh2 expression level 
 
The data collected so far proved that VE-cadherin is able to regulate PcG protein activity at 
claudin-5, VE-PTP and vWf promoters by finely tuning PcG protein recruitment, through 
the regulation of FoxO1/β-catenin nuclear availability and Ezh2/VE-cadherin association. 
However, we noticed an additional mechanism through which VE-cadherin expression and 
clustering might regulate PcG activity. Ezh2 protein levels were higher in confluent VEC-
null cells than in confluent VEC-positive cells (Figure 30). This difference was at least in 
part due to a higher level of transcription of Ezh2 gene in VEC-null cells (Figure 45).  
 
     
Figure 45 Ezh2 transcript levels are reduced in VEC-positive ECs 
qRT-PCR analysis of Ezh2 in confluent VEC-null and VEC-positive. The levels of mRNA are normalized to 
18S. Columns are means ± s.d. of triplicates from representative experiments (n=3). t-test: * P<0.01.  
 
Ezh2 has been shown to be a target of hypoxia inducible factor (Hif)1α  124. Interestingly, 
we observed that Hif1α was increased both at the mRNA and protein level in VEC-null 
cells (Figure 46). 
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Figure 46 Hif1α  transcript and protein levels are reduced in VEC-positive ECs 
(a) qRT-PCR analysis of Hif1α in confluent VEC-null and VEC-positive. The levels of mRNA are 
normalized to 18S. Columns are means ± s.d. of triplicates from representative experiments (n=3). t-test: * 
P<0.01. (b) WB analysis of Hif1α in extracts from confluent VEC-null and VEC-positive ECs. Vinculin was 
used as loading control. 
 
 
Moreover, Ezh2 is upregulated by E2f transcription factors in endothelial cells  125. E2f 
factors are negatively regulated by the binding to hypophosphorylated retinoblastoma 
protein (pRb)  126. Confluent VEC-positive cells showed a much higher level of 
hypophosphorylated pRb than VEC-null cells (Figure 47), in line with a role for E2f 
factors in determining a reduced Ezh2 expression in such cell type. 
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Figure 47 pRb is hypophosphorylated in VEC-positive ECs 
WB analysis of hyperphosphorylated (higher band) and hypophoshorylated pRb (lower band) in extracts 
from confluent VEC-null and VEC-positive ECs. Tubulin was used as loading control. 
 
 
Polycomb protein overexpression is accompanied by Claudin-5 repression in human 
ovarian cancer 
 
Previous reports showed that EZH2 is overexpressed by tumour cells and tumour ECs in 
66% and 67% of human epithelial ovarian cancer samples analysed, respectively 120, 138. 
Increased EZH2 expression in cancer cells and ECs strongly correlates with poor 
prognosis. We therefore sought to investigate if the reported higher EZH2 levels in human 
ovarian cancer specimens have an effect on Claudin-5 expression. 
By performing double IHC analysis we found that normal ovarian tissue expresses very 
low, if any, EZH2, both in stromal cells and ECs, as expected for a non-proliferative 
healthy tissue, while Claudin-5 is massively expressed by virtually every vessel (Figure 
48a). Conversely, serous surface papillary ovarian carcinomas show a marked increase in 
EZH2 protein expression in tumour cells compared to the healthy counterpart, in line with 
reports by Lu et al. Interestingly, Claudin-5 is strongly reduced in tumour vasculature and 
this is paralleled by the presence of ECs expressing high EZH2 (Figure 48b). These data 
show that, at least in the context of serous surface papillary ovarian carcinomas, EZH2 and 
Claudin-5 levels show an inverse expression pattern in ECs suggesting that Claudin-5 is a 
PcG protein-target gene in vivo.                   
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Figure 48 IHC analysis of EZH2 and Claudin-5 in normal and malignant ovarian tissue 
Representative images of double IHC analysis showing EZH2 (green) and Claudin-5 (red) in normal ovarian 
tissue (a) and serous surface papillary ovarian carcinoma (b). Black arrows in (b) indicate blood vessels that 
contain at least one EZH2-positive ECs and that are simultaneously Claudin-5-negative. Black arrowheads 
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indicate vessels that express CLAUDIN-5 but no detectable EZH2. (c) Double IHC negative control (primary 
Abs omitted) staining performed on ovarian tissue. 
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DISCUSSION 
 
We demonstrate here the essential role of VE-cadherin expression and clustering at AJs 
for the proper expression of endothelial-specific genes linked to vascular stability such as 
claudin-5, VE-PTP and vWf. These results confirm and extend previous observations about 
VE-cadherin-mediated regulation of claudin-5 expression in ECs  26. We found that 
claudin-5, VE-PTP and vWf are a core set of endothelial-specific genes that are positively 
regulated by EC-confluency (Figure 10, 11 and 12) and negatively regulated by the activity 
of FoxO1 and β-catenin (Figure 14, 15 and 16). This is in agreement with the presence of 
FoxO1 and Tcf/β-catenin-binding sites in the promoter regions of all three analysed genes. 
Of note, we found also that claudin-5, VE-PTP and vWf are epigenetically regulated by the 
activity of PcG and TrxG proteins (Figure 20 and 22), depending on the state of cell 
confluence and AJ organization. Our data point to a role for FoxO1 and β-catenin in the 
recruitment of PcG proteins to the promoter of claudin-5, VE-PTP and vWf, which is 
necessary to induce gene repression (Figure 31, 32 and 35). Moreover, VE-cadherin 
facilitates vascular stability gene expression by sequestering Ezh2 at the plasma membrane 
and this association is dependent on β-catenin- and p120-VE-cadherin binding (Figure 41 
and 42). Finally, we show evidence of an inverse expression pattern of endothelial EZH2 
and Claudin-5 in vivo in human ovarian cancer specimens further supporting the 
hypothesis of an epigenetic transcriptional regulation of Claudin-5 (Figure 48). 
This, to our knowledge, proves for the first time that AJ organisation can influence in 
multiple ways gene expression at the epigenetic level and provides new insights into the 
molecular mechanisms governing vascular stabilisation. Here we propose that the presence 
of VE-cadherin in ECs is necessary to initiate a vascular stability transcriptional 
programme comprising claudin-5, VE-PTP and vWf and likely other yet uncharachterized 
genes. VE-cadherin expression and clustering modulates several genes involved in 
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different aspects of cellular homeostasis. Among these genes we decided to focus on 
claudin-5, VE-PTP and vWf  because of their well-known EC-restricted expression pattern 
and for their previously reported role in promoting vascular stability.  
Our findings about EC-confluence-mediated upregulation of claudin-5, VE-PTP and 
vWf are in line with data present in the literature. For instance, Nottebaum and coworkers 
noticed an increase of VE-PTP junctional localization and a partial overlap of VE-PTP 
with VE-cadherin staining in long-confluent mouse bEnd.3 endothelioma cell line  76. In 
addition, Howell et al. reported that confluent HUVECs contain a larger pool of vWf 
protein compared to sub-confluent cells  127.  
Conversely, claudin-5, VE-PTP and vWf are negatively regulated by the activity of 
FoxO1 and β-catenin (Figure 14, 15 and 16). Our findings are in line with the previously 
reported role of FoxO1 as a transcription factor with vascular destabilising functions. 
Indeed, FoxO1 activity leads to an impairment in tube formation and VEGF-dependent 
migration in HUVECs  51. In particular, FoxO1 inhibits the expression of endothelial eNOS 
and promotes that of Ang-2, both effects leading to a destabilised vessel phenotype  74, 128. 
Our data further support the role of FoxO1 as an important regulator of angiogenesis and 
vascular remodelling, showing that FoxO1 activity is linked to vessel destabilisation, as it 
exerts an inhibitory effect on the expression of genes playing key roles in junctional and 
extracellular matrix stability such as claudin-5, VE-PTP and vWf.  
Of note, we found also that claudin-5, VE-PTP and vWf are epigenetically regulated by 
the activity of PcG and TrxG proteins, depending on the state of cell confluence and AJ 
organisation. We observed that the presence of VE-cadherin itself is able to modulate PcG 
protein levels and activity. In the absence of VE-cadherin, ECs display higher levels of 
PcG proteins and a higher enrichment in H3K27me3 on the TSS of the analysed gene, 
which correlate with their repressed state (Figure 20). As shown in Figure 45, VEC-null 
ECs display higher Ezh2 transcript levels if compared to VEC-positive ECs. This is in line 
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with the observed higher activity of both E2f transcription factors and Hif1α, two well-
known activators of Ezh2 gene expression  124, 129 (Figure 46, 47 and 49).  
 
    
 
Figure 49 Schematic representation of PcG-protein-dependent regulation of vascular stability genes in 
VEC-null ECs 
In the absence of VE-cadherin the FoxO1/β-catenin/Tcf4 complex binds to the promoter of claudin-5, VE-
PTP and vWf and represses their expression with the help of PcG proteins which catalyse the deposition of 
the repressive histone mark H3K27me3. 
 
Conversely, VEC-positive ECs display a reduced PcG protein occupancy on the TSS of 
claudin-5, VE-PTP and vWf, compared to VEC-null cells. This is due to the 
aforementioned transcriptional mechanisms (less E2f and Hif1α activity), to the reduced 
FoxO1 and β-catenin nuclear levels and to the ability of VE-cadherin to sequester part of 
Ezh2 out of the nucleus. Furthermore VE-cadherin expression is likely to promote post-
translational modifications that modulate PcG protein activity  130 (Figure 50). 
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Interestingly, AKT is reported to phosphorylate Ezh2 on serine 21 resulting in an 
inhibition of H3K27me3 deposition  131. Given that the expression and clustering of VE-
cadherin in ECs promotes AKT activation  26, we hypothesize that this mechanism could 
also be involved in dampening PcG protein activity in VEC-positive ECs. Future work will 
be required to demonstrate this hypothesis but unfortunately specific reagents recognizing 
phosphorylated PcG proteins are still missing. Strikingly, our biochemical data suggest that 
the presence of VE-cadherin is able to decrease PcG protein activity in ECs by 
sequestering at least part of cellular Ezh2 protein away from the nucleus in a p120- and β-
catenin-dependent manner (Figure 41, 42 and 50). VE-cadherin/Ezh2 interaction takes 
place mainly at the plasma membrane, as suggested by membrane protein biotinylation 
experiments (Figure 40). VE-cadherin/Ezh2 interaction is quite strong as it could be 
observed also in CoIPs from murine total lung lysates in the absence of crosslinking 
reactions (Figure 38). Ezh2 binding to VEC was further confirmed by using a second 
commercial anti-Ezh2 Ab (Rabbit polyclonal 07-689 Millipore) (Figure 37). It is also 
worth to point out that, in ECs, Ezh2 sequestration at the plasma membrane is selectively 
exerted by VE-cadherin, as we could not see any Ezh2 binding to N-cadherin neither in 
VEC-positive nor in VEC-null ECs (which express more N-cadherin compared to VEC-
positive ECs  19). VE-cadherin specifically recruits Ezh2 among PcG proteins, as Suz12 IP 
did not shows any co-immunoprecipitated VEC (Figure 39). Still, we do not have evidence 
supporting a direct binding of Ezh2 to VE-cadherin, nor to p120 or β-catenin, so we cannot 
rule out that Ezh2 sequestration to VE-cadherin at the plasma membrane might be 
mediated by another protein binding to VE-cadherin cytoplasmic tail. To understand this 
aspect pull down assays combining full length proteins or deletion mutants are required.  
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Figure 50 Schematic representation of vascular stability gene activation in VEC-positive ECs 
The presence of VE-cadherin promotes the expression of claudin-5, VE-PTP and vWf vascular stability genes 
in multiple ways: 1) the nuclear exclusion of the transcription factor FoxO1 through PI3K/AKT pathway 
activation, 2) the β-catenin- and p-120-dependent sequestration of part of cellular Ezh2 at the plasma 
membrane, 3) the reduction in Ezh2 transcript levels and 4) the AKT-mediated post-translational 
modifications (PTM). These events cooperate to dampen PcG protein activity and to favour vascular stability 
gene expression. 
 
 
In the literature PcG proteins were previously reported to have atypical localizations, 
interactions and functions beside their well-known role as histone modifiers. For instance, 
Witte et al. showed that the PcG protein EED can be bound by the N-terminus of the HIV 
protein Nef and sequestered at the plasma membrane. This allows a de-repression of the 
HIV genome in order to permit Tat-dependent viral transcription  123. Su and coworkers, 
instead, showed that a cytosolic pool of Ezh2 exists at least ex vivo in thymocytes and 
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purified lymph node T cells and in several cell lines such as Jurkat, mouse embryonic 
fibroblasts (MEFs) and HEK-293. The authors also show that cytosolic Ezh2 is bound to 
Suz12, Eed and the GTP/GDP exchange factor Vav1 and still retains histone methyl 
transferase activity although its cytosolic substrates remain unknown. Strikingly, T-cell-
restricted Ezh2 deletion does not affect H3K27me3 levels while it impairs T-cell Receptor 
(TCR)-dependent actin polymerization acting upstream of Cdc42 and Rac1  122. Altogether 
these data suggest that, even if the major role of PcG proteins remains modifying histone 
tails to regulate gene expression, several members of PcG proteins could reside and work 
also in cellular compartments different from the nucleus exerting functions unrelated to 
histone modification. 
As stated above, different mechanisms most likely work together to reduce PcG protein 
activity in VEC-positive ECs (Figure 50) resulting in high H3K4me3 levels on the TSS of 
claudin-5, VE-PTP and vWf  that overcome H3K27me3 and facilitate gene expression. We 
can speculate that these higher H3K4me3 levels in VEC-positive ECs might be due to a 
higher activity of TrxG protein complexes. Set1A-, Set1B- and Mll-containing TrxG 
complexes are reported in the literature to be the only multiprotein complexes able to 
catalyse the deposition of the activating histone mark H3K4me3  83, 101. Future work will be 
required to address how TrxG proteins are recruited to these loci and how they act at the 
molecular level in order to turn on the expression of claudin-5, VE-PTP and vWf. 
The presence of PcG protein-derived and TrxG protein-derived histone marks 
(H3K27me3 and H3K4me3, respectively) on the TSS of claudin-5, VE-PTP and vWf is not 
trivial given the well documented roles of these two histone marks in regulating the 
expression of a wide variety of target genes. PcG proteins have been extensively studied 
for their involvement in the regulation of developmental genes in ES cells, where they 
often induce the establishment of the so-called "bivalent domains", regions of the genome 
harbouring both H3K27me3 and H3K4me3 histone marks  82, 83. Bivalent domains are 
eventually resolved during differentiation leading to either H3K27me3-marked (repressed) 
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or H3K4me3-marked (active) regions. In this way, the regulated developmental genes are 
believed to be maintained repressed but poised for activation  82. Claudin-5, VE-PTP and 
vWf simultaneously show both H3K27me3 and H3K4me3 on their TSSs and the balance 
between these two histone marks depends on cell confluence and junction organization. 
We suggest therefore that bivalent domains exist in ECs and are involved in keeping 
claudin-5, VE-PTP and vWf genes in a repressed/poised for activation state in VEC-null or 
sparse VEC-positive cells. Once ECs reach confluence and VE-cadherin is expressed and 
clustered at AJs, bivalent domains are resolved towards the full activation state of claudin-
5, VE-PTP and vWf, leading to a quiescent, mature and stabilised endothelial cell layer.  
Despite the huge improvements that were made in the last decade in the field of PcG 
protein biology, we still do not fully understand the molecular mechanisms that drive PcG 
protein binding to target genes. PcG protein targeting is much better defined in Drosophila 
melanogaster where PcG proteins "land" on cis-regulatory binding platforms called PREs 
ensuring the consequent repression on target genes  86, 87, 132. Conversely, in mammals, very 
little is known about how PcG proteins are targeted to specific genes. Previous 
publications suggested that mammalian PcG proteins might be recruited to chromatin by 
associating with DNA-binding partners  84, 86, 87, 100. For instance, the transcription factor 
Snail1 has been shown to interact with members of the PRC2 complex, such as Suz12 and 
Ezh2, targeting them to the DNA to specifically inhibit the expression of E-cadherin  100. 
Recently, two other transcription factors were reported to be involved in the regulation of 
PcG targeting. Mulero et al. showed that Nuclear factor of kappa light polypeptide gene 
enhancer in B cells inhibitor, alpha (IκBα) interacts with Ezh2, Suz12 and Bmi1 and that, 
following TNFα treatment, Suz12 detaches from IκBα-target genes suggesting that IκBα 
could regulate PcG protein association to these regions  133. Another example of PcG 
protein-recruiting factor is the RE1-silencing transcription factor (REST). Dietrich and co-
workers showed that, in NT2-D1 human teratocarcinoma cells and mouse embryonic stem 
(mES) cells, REST interacts with both PRC1 and PRC2 and is required for PcG protein 
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binding to a subset of REST target genes involved in neuronal differentiation  134. These 
and many other reports in the literature suggest that PcG protein targeting could be 
strongly cell type- and genomic context-dependent. 
 Likewise, in our study we found that the cooperation between PcG proteins and 2 new 
putative recruiting factors, FoxO1 and β-catenin, is required for the proper repression of 
specific genes in ECs. The overexpression of FKHR-TM in VEC-positive cells increased 
H3K27me3 levels on the TSS of claudin-5, VE-PTP and vWf correlating with their 
repressed state (Figure 31, 32, 51 and see Taddei et al., 2008). Our experiments 
demonstrate also that PcG proteins form a complex with FoxO1 both in endogenous and 
overexpression conditions. Counterintuitively, we found that PcG proteins interact with 
FoxO1 also in VEC-positive ECs. We still do not know the function of this interaction, 
however in this cell type the complex is not targeted to chromatin, as VE-cadherin 
expression promotes FoxO1 phosphorylation and nuclear exclusion and no binding of 
either FoxO1 or β-catenin was detected to any of the promoter regions of the analysed 
genes in confluent VEC-positive cells (Figure 18 and 19)  26, 47, 48. 
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Figure 51 Proposed model for PcG-protein recruitment by FoxO1 (FKHR-TM) in VEC-positive ECs 
Upon FKHR-TM overexpression, PcG proteins are recruited to the promoters of claudin-5, VE-PTP and vWf 
and, through the deposition of the repressive histone mark H3K27me3, these vascular stability genes undergo 
repression.  
 
These data explain also why PcG protein overexpression in VEC-positive cells leads to 
a significant reduction of claudin-5, VE-PTP and vWf expression which, however, does not 
reach the levels of repression observed in VEC-null cells. Indeed, in confluent VEC-
positive cells, the amount of de-phosphorylated (active) FoxO1 available in the nucleus 
and able to actively target PcG proteins to chromatin is strongly reduced  26, rendering the 
recruiting mechanism inefficient.  
Concerning β-catenin, our results point to a dual role for this protein in the regulation of 
claudin-5, VE-PTP and vWf expression. While membrane-localized β-catenin allows 
Ezh2/VE-cadherin association (Figure 50), facilitating vascular stability gene expression, 
on the other hand β-catenin nuclear localization seems to stabilise PcG protein association 
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to target gene promoters, likely strengthening FoxO1/DNA binding (Figure 49). In line 
with this hypothesis, the inhibition of β-catenin association to DNA-bound Tcf4 reduces 
PcG protein targeting to claudin-5 and VE-PTP promoters, while Ezh2 binding to vWf 
promoter is only mildly reduced upon TCF4dn overexpression (Figure 35). Future work 
will be required to better dissect the molecular mechanisms involved in such dual role. 
Our results however suggest that inhibiting PcG activity is not sufficient for a full 
reactivation of the analysed vessel stabilisation genes. In fact, PcG protein knockdown in 
VEC-null ECs led only to a modest de-repression of claudin-5, VE-PTP and vWf reaching 
an expression level far lower than that observed in confluent VEC-positive ECs. This 
parallels evidence in literature showing that many genes are unable to undergo a full 
reactivation after PcG protein knockdown. For example SW-60 cells stably expressing 
siRNA against either Suz12 or Ezh2 show only a mild de-repression of E-cadherin gene  
100. Our results therefore suggest two possible scenarios. PRC1 has been reported to bind 
certain target genes even in the absence of PRC2 recruitment  135, 136. This complex itself 
could therefore be responsible for maintaining claudin-5, VE-PTP and vWf in a repressed 
state. Alternatively, VEC-null ECs might lack one or more activators of transcription 
needed to accomplish the full expression of claudin-5, VE-PTP and vWf. Previous 
publications pointed at sex-determining region (SRY)-box (SOX) and E twenty six (ETS) 
factors as putative activators of claudin-5 and vWf transcription, respectively  112, 137, 138 and 
preliminary results suggest a lower expression of such TFs in the absence of VE-cadherin 
expression and clustering. Future work will be required to elucidate the possible 
involvement of these TFs or of the PRC1 complex in the regulation of the analysed genes. 
Vascular stabilisation is altered in many pathological conditions such as stroke and 
cancer, where blood vessels are strongly disorganised and present a high, uncontrolled 
permeability. Tumour vessels, for instance, display uneven pericyte coverage and ECs with 
disorganized cell-cell junctions, often detached from the basal membrane. This has 
profound consequences at the clinical level. Leaky vessels cause regions of severe 
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hypoxia, increased interstitial pressure and offer cancer cells a preferential route for 
metastatic dissemination  54. Thus, finding therapeutical approaches able to efficiently 
"normalise" abnormal vessels and restore the physiological control of permeability would 
be a huge improvement for cancer treatment allowing an increased delivery of 
chemotherapeutic drugs to tumour cells and creating a barrier against cancer cell 
intravasation and metastasis dissemination  54, 139. 
Recent publications showed vessel normalisation as an efficient approach for cancer 
treatment. For instance, Phd2 haploinsufficient mice show normalised tumour blood 
vessels, increased tumour perfusion, reduced cancer cell intravasation and metastasis and a 
better response to chemotherapy  139-141. PcG protein Ezh2 is emerging as a key player 
regulating neoplastic growth and tumour vessel organization  125, 142-144. Epithelial ovarian 
cancer patients expressing high levels of Ezh2 in tumour cells and ECs have worse 
prognosis  125, 142. In ovarian cancer-derived ECs Ezh2 has been proved to repress 
vasohibin1 (VASH1), an inhibitor of angiogenesis, by directly binding to its promoter, 
leading to abnormal and uncontrolled vessel growth in the tumour mass  125. The inhibition 
of Ezh2 by in vivo siRNA delivery or using available chemical inhibitors such as 3-
Deazaneplanocin A (DZnep) has effects both on tumour vessels and cancer cells  143, 144. 
These approaches lead to reduced tumour microvessel density and cancer cell proliferation 
while increasing vessel pericyte coverage and tumour cell apoptosis, resulting in tumour 
shrinkage  125, 143, 144. In addition to this, we found that human ovarian cancer specimens 
often show an increased EZH2 protein level both in tumour cells and in ECs, thus 
confirming what previously published by Sood and coworkers  125, 142. The higher EZH2 
expression in ECs is paralleled by a dramatic decrease in Claudin-5. Conversely, fimbriae 
(not shown) and ovary specimens from healthy donors show no detectable EZH2 
expression (neither in stromal cells nor in ECs) and a high expression of Claudin-5 in 
blood vessels (Figure 48). These findings suggest that an inverse correlation exists between 
the expression of EZH2 and Claudin-5 in vivo and could explain the very high interstitial 
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fluid pressure (IFP) observed in ovarian cancer tissues by Goel and coworkers  64. Indeed, 
lack of Claudin-5 in ovarian cancer could lead to an increase in vascular permeability to 
cells and solutes, causing a rise in IFP. More in vivo experiments are being performed to 
confirm such regulation also for VE-PTP and vWf. Data from several research groups  125, 
142-144 complement our results and support the idea that Ezh2 activity is linked to vascular 
proliferation and destabilisation. This makes Ezh2 an interesting therapeutic target that can 
be exploited to normalize destabilised tumour vessels in ovarian cancer, the fourth most 
common cause of cancer-related death in women and the most lethal tumour type in 
gynecological neoplasms  145, 146. In this perspective, acting on the VE-
cadherin/FoxO1/PcG pathway, for example through DZnep-induced Ezh2 inhibition, could 
result in the upregulation of claudin-5, VE-PTP and vWf in tumour ECs. This would re-
establish a correct vascular stability and permeability control and would efficiently 
obstruct metastatic cell intravasation.  
In conclusion, we found that VE-cadherin expression and clustering at endothelial cell-
cell junctions and the consequent modulation of the FoxO1/β-catenin pathway have broad 
effects on EC maturation, beyond the previously reported claudin-5 upregulation  26. 
Indeed, VE-cadherin, by indirectly inhibiting PcG protein activity via multiple 
mechanisms, drives the expression of a cluster of genes of key importance for vascular 
stabilisation including VE-PTP and vWf and likely others not yet identified. This, to our 
knowledge, proves for the first time that AJ organisation can influence gene expression at 
the epigenetic level and provides new insights into the understanding of vascular 
stabilisation control, which might help developing new therapeutic approaches for a set of 
pathologies characterized by vessel instability such as cancer. 
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